Part | Title |
---|---|
4717.0100 | [Repealed, 19 SR 1419; 19 SR 1637] |
PUBLIC SWIMMING POOLS | |
4717.0150 | APPLICABILITY. |
4717.0200 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.0250 | DEFINITIONS. |
4717.0275 | INCORPORATIONS BY REFERENCE. |
4717.0300 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.0310 | PLAN REVIEW FEES. |
4717.0350 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.0375 | INSPECTIONS; WATER SAMPLING. |
4717.0400 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.0450 | SUBMISSION OF PLANS AND SPECIFICATIONS. |
4717.0500 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.0600 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.0650 | POOL OPERATION AND MAINTENANCE; OPERATOR TRAINING. |
4717.0700 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.0750 | POOL RECORD. |
4717.0775 | REPORTING. |
4717.0800 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.0900 | [Repealed, 19 SR 1419; 19 SR 1637] |
POOLS; LIFEGUARDS; AND EQUIPMENT | |
4717.0950 | LIFEGUARD REQUIREMENT. |
4717.1000 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1050 | NO LIFEGUARD WARNING SIGN. |
4717.1100 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1200 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1250 | EMERGENCY TELEPHONE LOCATION. |
4717.1300 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1350 | POOL FACILITY CAPACITY. |
4717.1400 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1450 | LIFEGUARD STATIONS AND LIFESAVING EQUIPMENT. |
4717.1500 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1550 | POOL ACCESS RESTRICTION; FENCING. |
4717.1575 | POOL COVERS. |
4717.1600 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1650 | USER SANITATION AND SAFETY. |
4717.1700 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1750 | POOL WATER CONDITION. |
4717.1800 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1850 | DEPTH OF POOL WATER. |
4717.1900 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.1950 | POOL CLEANING. |
4717.2000 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.2100 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.2150 | WATER SUPPLY. |
4717.2200 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.2250 | SEWER SYSTEM. |
4717.2300 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.2350 | POOL STRUCTURE. |
4717.2400 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.2450 | MARKINGS AND LINES. |
4717.2500 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.2550 | RECIRCULATION SYSTEM. |
4717.2560 | RECIRCULATION RATE. |
4717.2570 | RECIRCULATION EQUIPMENT. |
4717.2580 | INLETS AND OUTLETS. |
4717.2590 | OVERFLOW GUTTERS. |
4717.2595 | SKIMMERS. |
4717.2600 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.2610 | DISINFECTANT AND CHEMICAL FEEDERS. |
4717.2620 | CHEMICAL HANDLING EQUIPMENT; PROTECTIVE EQUIPMENT. |
4717.2630 | USE OF GAS CHLORINE. |
4717.2650 | USE OF HYPOCHLORITE SOLUTION. |
4717.2700 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.2750 | USE OF EROSION FEEDERS. |
4717.2800 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.2850 | SAND FILTERS. |
4717.2900 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3000 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3050 | DIATOMACEOUS EARTH FILTERS. |
4717.3100 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3150 | CARTRIDGE FILTERS. |
4717.3200 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3250 | STEPS, LADDERS, HANDHOLDS, AND HANDRAILS. |
4717.3300 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3350 | DECKS AND WALKWAYS. |
4717.3400 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3450 | LIGHTING, VENTILATION, AND ELECTRICAL REQUIREMENTS. |
4717.3475 | STARTING BLOCKS AND PLATFORMS; SLIDES; OTHER OBJECTS. |
4717.3500 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3550 | DRESSING ROOMS. |
4717.3600 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3650 | TOILETS, LAVATORIES, SHOWERS, AND DRESSING ROOMS. |
4717.3675 | DRINKING FOUNTAINS. |
4717.3700 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3750 | STANDARDS FOR POOLS WITH DIVING. |
4717.3800 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3850 | SPA POOLS. |
4717.3870 | POOL SLIDES. |
4717.3875 | FLUME WATER SLIDES. |
4717.3900 | [Repealed, 19 SR 1419; 19 SR 1637] |
4717.3950 | WAVE POOLS. |
4717.3970 | POOL CLOSURE. |
4717.3975 | VARIANCE. |
ON-LAND DISPOSAL FACILITIES FOR SEWAGE AND OTHER WASTES FROM MARINE TOILETS EQUIPPED WITH RETENTION DEVICES |
|
4717.4000 | PUMP. |
4717.4100 | SUCTION HOSE. |
4717.4200 | DISCHARGE HOSE. |
4717.4300 | SEWAGE OR OTHER WASTE DISPOSAL REQUIREMENTS. |
4717.4400 | WATER SUPPLY REQUIREMENTS. |
4717.4500 | PLAN APPROVAL. |
4717.4600 | [Repealed, 14 SR 1874] |
4717.4700 | [Repealed, 14 SR 1874] |
4717.4800 | [Repealed, 14 SR 1874] |
4717.4900 | [Repealed, 14 SR 1874] |
4717.5000 | [Repealed, 14 SR 1874] |
4717.5100 | [Repealed, 14 SR 1874] |
4717.5200 | [Repealed, 14 SR 1874] |
4717.5300 | [Repealed, 14 SR 1874] |
4717.6000 | [Repealed, 15 SR 1842] |
4717.6100 | [Repealed, 15 SR 1842] |
4717.6200 | [Repealed, 15 SR 1842] |
4717.6300 | [Repealed, 15 SR 1842] |
4717.6400 | [Repealed, 15 SR 1842] |
4717.6500 | [Repealed, 15 SR 1842] |
4717.6600 | [Repealed, 15 SR 1842] |
4717.6700 | [Repealed, 15 SR 1842] |
4717.6800 | [Repealed, 15 SR 1842] |
4717.6900 | [Repealed, 15 SR 1842] |
VARIANCES | |
4717.7000 | VARIANCE REQUEST. |
4717.7010 | CRITERIA FOR DECISION; CONDITIONS. |
4717.7020 | NOTIFICATION OF DECISION. |
4717.7030 | EFFECT OF ALTERNATIVE MEASURES OR CONDITIONS. |
4717.7040 | RENEWAL OF VARIANCE. |
4717.7050 | DENIAL, REVOCATION, OR REFUSAL TO RENEW; APPEALS. |
4717.7100 | [Repealed, 33 SR 1792] |
4717.7150 | Repealed by subpart |
4717.7200 | [Repealed, 33 SR 1792] |
4717.7300 | [Repealed, 33 SR 1792] |
4717.7400 | [Repealed, 33 SR 1792] |
HEALTH RISK LIMITS | |
4717.7500 | TABLE OF HEALTH RISK LIMITS. |
4717.7600 | [Repealed, 33 SR 1792] |
4717.7650 | [Repealed, 33 SR 1792] |
4717.7700 | [Repealed, 33 SR 1792] |
4717.7750 | [Repealed, 33 SR 1792] |
4717.7800 | [Repealed, 33 SR 1792] |
4717.7810 | HEALTH RISK LIMITS; PURPOSE AND SCOPE. |
4717.7820 | DEFINITIONS. |
4717.7830 | FOR TOXIC EFFECTS OTHER THAN CANCER. |
4717.7840 | FOR CANCER. |
4717.7850 | USE OF MAXIMUM CONTAMINANT LEVELS. |
4717.7860 | HEALTH RISK LIMITS TABLE. |
4717.7865 | HEALTH RISK LIMITS FOR TRICLOSAN. |
4717.7870 | EVALUATING CONCURRENT EXPOSURES TO MULTIPLE CHEMICALS. |
4717.7880 | MULTIPLE CHEMICAL HEALTH RISK LIMITS: NONCANCER. |
4717.7890 | MULTIPLE CHEMICAL HEALTH RISK LIMITS: CANCER. |
4717.7900 | CHEMICAL BREAKDOWN PRODUCTS. |
HEALTH RISK VALUES | |
4717.8000 | PURPOSE AND SCOPE. |
4717.8050 | DEFINITIONS. |
4717.8100 | TABLE OF CHRONIC HRVs. |
4717.8150 | TABLE OF SUBCHRONIC HRVs. |
4717.8200 | TABLE OF ACUTE HRVs. |
4717.8250 | TABLE OF MHRVs FOR MULTIMEDIA EXPOSURE TO AIR TOXICS. |
4717.8300 | EQUATIONS FOR CALCULATION OF HRVs FOR NONCARCINOGENIC EFFECTS OF TOXICANTS. |
4717.8350 | EQUATION FOR CALCULATION OF MHRV FOR NONCARCINOGENIC EFFECTS OF TOXICANTS. |
4717.8400 | EQUATION FOR CALCULATION OF HRVs FOR CARCINOGENS. |
4717.8450 | EQUATION FOR CALCULATION OF MHRV FOR CARCINOGENS. |
4717.8500 | EQUATIONS FOR CALCULATION OF HRVs FOR ACUTE TOXICITY. |
CANCER INDEX AND HAZARD INDEX | |
4717.8550 | PROCEDURE FOR DETERMINING CANCER INDEX FOR SIMULTANEOUS EXPOSURE TO MULTIPLE CARCINOGENS. |
4717.8600 | PROCEDURE FOR DETERMINING HAZARD INDEX FOR ASSESSING SIMULTANEOUS EXPOSURE TO MULTIPLE TOXICANTS WITH NONCARCINOGENIC EFFECTS. |
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Parts 4717.0150 to 4717.3975 establish operation and maintenance, design, installation, and construction standards for public pools and facilities related to them.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
For the purposes of parts 4717.0150 to 4717.3975, the terms defined in this part have the meanings given them.
"Commissioner" means the commissioner of health or the commissioner's authorized representative.
"Operator" means the individual designated by the owner as responsible to operate and maintain the public pool in compliance with parts 4717.0150 to 4717.3975.
"Owner" means the person who owns the public pool and is responsible for compliance with parts 4717.0150 to 4717.3975.
"Person" means an individual, firm, partnership, association, limited liability company, corporation, company, government agency, club, or organization of any kind.
"Pool" means any structure, chamber, or tank containing an artificial body of water for swimming, diving, relaxation, or recreational use including special purpose pools and wading pools.
"Private residential pool" means a pool connected with a single-family residence or owner-occupied duplex, located on private property under the control of the homeowner, the use of which is limited to family members or the family's invited guests. A private residential pool is not a pool used as part of a business.
"Public pool" has the meaning given in Minnesota Statutes, section 144.1222, subdivision 4, paragraph (d).
"Spa pool" means a hot water pool intended for seated recreational use with a water agitation system in addition to the recirculation system. Spa pool is synonymous with the term "whirlpool."
"Special purpose pool" means a pool intended to accommodate a use other than normal swimming, diving, or wading. A special purpose pool includes, but is not limited to, spa pools, pools used for water therapy, dedicated plunge pools, flume water slides, and wave pools.
"Trained operator" means an individual who meets the requirements of part 4717.0650, subpart 5.
"Wading pool" means any pool with a maximum depth of 24 inches used or designed to be used exclusively for wading.
19 SR 1419; 19 SR 1637; L 2008 c 328 s 13
May 11, 2009
This part indicates documents, specifications, methods, and standards that are incorporated by reference in parts 4717.0150 to 4717.3975. This material is not subject to frequent change and is available from the source listed, for loan or inspection from the Barr Library of the Minnesota Department of Health, or through the Minitex interlibrary loan system.
American Public Health Association, "Standard Methods for the Examination of Water and Wastewater," 18th edition (1992), 1015 Fifteenth Street NW, Washington, D.C., 20005.
American Society for Testing Materials (ASTM) Standard F1346-91 (1991) "Standard Performance Specification for Safety Covers and Labeling Requirements for All Covers for Swimming Pools, Spas and Hot Tubs," 100 Barr Harbor Drive, West Conshohocken, PA 19428-2959.
NSF International, Standard 50 "Circulation System Components for Swimming Pools, Spas or Hot Tubs," May 1992, 3475 Plymouth Road, P.O. Box 1468, Ann Arbor, MI 48106.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
All plans for swimming pool construction, installation, or alteration submitted to the commissioner of health for review and approval under part 4717.0450 must be accompanied by the fee specified in this part:
L 1987 c 403 art 1 s 8 subd 2; MS s 16A.128; 144.05; 144.12; 144.122; 144.123; 145.05; 145A.02; 157.01
12 SR 1660; 16 SR 2780; 19 SR 1419; 19 SR 1637
October 11, 2021
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The commissioner is authorized to inspect and sample the water in public pools for compliance with parts 4717.0150 to 4717.3975.
The commissioner has the right of entry at any reasonable hour to ensure compliance with parts 4717.0150 to 4717.3975.
The commissioner may collect and examine water samples for compliance with part 4717.1750 at any reasonable hour.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
No public pool shall be constructed, installed, or materially altered until complete plans and specifications are submitted to the commissioner in duplicate and approved by the commissioner.
Once a plan is approved by the commissioner, no modification affecting the safety and sanitation features of the public pool shall be made without prior approval of the commissioner.
The pool and related facilities must be built in accordance with the approved plan unless prior approval of changes are given in writing by the commissioner.
Projects that include design features not specifically addressed in parts 4717.0150 to 4717.3975 must be reviewed in the design development stage. Those design features shall be permitted only where the pool owner demonstrates that safety and water quality can be maintained based on the current technology and information provided to the commissioner at the time of review. The commissioner may require special provisions to assure that safety and water quality are maintained. Special provisions may include continuous supervision.
Plans and specifications for pool construction and any existing pool alteration must contain:
the name, address, and telephone number of the organization or individual who prepared the plans and specifications;
plans for the pool drawn to scale, with top and profile views, that include dimensions and all equipment or appurtenances such as skimmers, gutters, inlets, drains, lights, diving boards, slides, ladders, steps, and handrails;
a plan of the recirculation system showing all pipe sizing, fittings, valves, gauges, and equipment connections;
a plan for the deck and equipment room that shows all drains, sumps, deck slopes, and air gaps at discharges to the sewer from all deck drains, pool drains, and recirculation system drains;
The owner of the pool or the owner's agent must notify the commissioner and any local jurisdiction which regulates pool use at the time the pool is complete to permit inspection of the pool and related facilities.
The pool must not be placed into public use until the commissioner's inspection shows compliance with parts 4717.0150 to 4717.3975.
If sustained construction of the pool does not begin within one year of the plan approval date, the approval is no longer valid.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
A public pool, pool equipment, and related facilities and equipment must be maintained in a properly operating condition.
A public pool and the related facilities and equipment must be operated and maintained in working condition by a person who is designated as responsible for compliance with parts 4717.0150 to 4717.3975 and ensures that the pool poses no threat to public health or safety. The owner shall be responsible for the operation of the pool and related facilities and compliance with parts 4717.0150 to 4717.3975. Where another person has operational authority under an agreement with the owner, that person also has responsibility for the operation of the pool and related facilities and for compliance with parts 4717.0150 to 4717.3975.
The owner or operator of the pool must designate a trained operator who is responsible for the direct operation of the pool whenever the pool is open for use.
The trained operator must be responsible for the daily operation of the pool and ensure that required testing is done and records are maintained. The trained operator, or a designated alternate trained operator, must be able to respond to emergency, unsafe and unsanitary conditions at any time the pool is open for use.
The trained operator must assure that other individuals who assist with chemical monitoring and pool equipment operation are trained for those functions.
An operations manual must be available that provides operational information relating to all pool equipment.
The owner or operator must ensure that the designated trained operator is trained to operate the pool in compliance with parts 4717.0150 to 4717.3975.
The trained operator must be trained in safe chemical handling and the use of protective equipment in addition to pool operation and sanitation described in items B to F.
Until January 1, 1997, any operator is eligible for certification through attendance at and successful completion of a pool operator's training course.
After January 1, 1997, the trained operator must be certified as successfully completing a pool operator training course as specified in item E.
A certified trained operator must successfully complete a training course as specified in item E at least once every five years after January 1, 1997.
Acceptable training courses are:
the Pool and Hot Tub Alliance Certified Service Technician (CST) and Certified Maintenance Specialist (CMS) and Certified Hot Tub Technician (CHTT) courses. Both CST and CMS are required for operation of pools. CHTT is required for operation of spas and hot tubs;
After January 1, 1997, a copy of the trained operator's training certificate must be posted at the facility whenever the pool is open for use.
19 SR 1419; 19 SR 1637; 46 SR 175
October 11, 2021
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
A record of a public pool's operation and routine maintenance must be kept by the operator. The record must be maintained for six years. The record must include the following for each day the pool is open to use:
the operating periods of recirculation pumps and filters and corresponding rate-of-flow meter readings;
any other pool chemistry measurements taken, although not required to be recorded daily, such as alkalinity and cyanuric acid concentrations;
any accidents or injuries requiring assistance from a lifeguard, attendant, or emergency medical personnel.
19 SR 1419; 19 SR 1637
May 11, 2009
All pool incidents resulting in death or serious injury that require assistance from emergency medical personnel must be reported to the commissioner by the owner or the owner's agent by the end of the next working day.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
An individual currently certified in first aid and adult, child, and infant cardiopulmonary resuscitation must be on duty at all times the pool is open to use, unless a sign warning that a lifeguard is not present is posted as specified in part 4717.1050.
The individual must have a Red Cross lifeguard certification or equivalent and be responsible for user supervision, safety, and sanitation at all times the pool is in use.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
When a lifeguard is not on duty at a public pool open to use, a warning sign must be placed in plain view.
The sign must state in clear, legible letters at least four inches high: "Warning - No lifeguard on duty."
The sign must state in clear, legible letters at least one inch high: "Children must not use the pool without an adult in attendance."
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
A pool with a lifeguard present must have a telephone in or immediately adjacent to the pool area. When a telephone is provided, the emergency number must be posted. When a telephone is not located in the pool enclosure, a sign placed in plain view must indicate the location of the nearest telephone available to a pool user and the emergency number.
19 SR 1419; 19 SR 1637
October 11, 2021
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The capacity for the pool, determined according to subpart 2, must be posted in the pool enclosure area.
User capacity must be determined as specified in this subpart.
One person is permitted for each 15 square feet of pool water surface in areas of the pool with five feet or less in water depth.
One person is permitted for each 25 square feet of pool water surface in areas of the pool over five feet in water depth.
Spa pools must be limited to one user for each three linear feet of seating space provided in the spa pool, measured along the front edge of the seats.
19 SR 1419; 19 SR 1637; 46 SR 175
October 11, 2021
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
At any time a pool with more than 2,250 square feet of water surface is operated primarily for unorganized use, the pool must have an elevated lifeguard platform or chair. In a pool with 4,000 square feet or more of water surface, additional elevated platforms, or chairs must be located to provide a clear, unobstructed view of the pool bottom in the area under surveillance.
Except for a spa pool or wading pool, not less than one unit of lifesaving equipment as described in subpart 3, must be at every public pool. One unit must be provided for each 2,000 square feet of water surface or fraction thereof.
One unit of lifesaving equipment is:
a ring buoy attached to a 3/16 inch manila, or equivalent material, rope that is 1-1/2 times the pool width, but not over 60 feet; and
a lifepole or shepherd's crook pole with blunted ends and a minimum fixed length of 12 feet; or
Lifesaving equipment must be mounted in conspicuous places, distributed around the pool deck, at lifeguard chairs or at another readily accessible location. The equipment must be plainly marked "For emergency use only." Equipment must be kept in repair and ready condition. No one may tamper with, use for any purpose other than its intended use, or remove equipment from its established location, except for emergency use.
Every pool where a lifeguard is present must have a first aid kit filled and ready for use and a spine board with ties. The spine board must be within the pool enclosure. The first aid kit must contain at least:
19 SR 1419; 19 SR 1637
October 11, 2021
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Access to a public pool must be controlled to effectively prevent the entrance of children.
Where fencing is used to control access, it must comply with subparts 2 to 6 except as noted in item B, subitem (2).
Access to a public pool within a building or enclosure must be controlled:
by locating the pool in a separate room with self-latching doors that restrict access to the room; or
with fencing or a comparable barrier which is at least four feet high and has self-closing, self-latching doors or gates.
Exception: poolside guest rooms, corridors adjacent to poolside guest rooms, and poolside activity areas may be within the pool enclosure.
Fencing in existence prior to January 4, 1995, that is less than five feet high must:
Fencing for a wading pool enclosure must be at least 42 inches high for existing installations and 48 inches high for new installations.
New chain link fencing must not exceed 1-1/2 inch mesh for fencing less than eight feet high. New chain link fencing eight foot high or higher must have mesh which does not exceed two inches.
19 SR 1419; 19 SR 1637
May 11, 2009
If a pool cover is used, any new cover must comply with ASTM Standard F1346-91.
Pool covers must be maintained in a clean and sanitary condition to preclude contamination of the pool water.
If the deck area is accessible when the cover is in place, a fully secured safety cover must be used.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Placards and pictorial representations, where appropriate, embodying the requirements in this part must be posted in plain view in the pool room or enclosure and in the dressing rooms of all public pools. Lettering must be clear, legible, and at least one-fourth inch high.
No person with or suspected of having a communicable disease which could be transmitted through use of the pool shall work at or use any public pool.
A person with any considerable area of exposed subepidermal tissue, open blisters, or cuts must be warned that these may become infected and advised not to use the public pool.
Any person using a public pool must take a cleansing shower using warm water and soap and thoroughly rinse off all soap before entering the pool enclosure. A user leaving the pool to use the toilet must take a second cleansing shower before returning to the pool enclosure. A person who exercises, applies lotion, or uses a sauna or steam room must shower before using the pool.
Spitting, spouting water from the mouth, and blowing the nose in the pool is prohibited.
No running or boisterous or rough play, except supervised water sports, is permitted in the pool, in dressing rooms or shower rooms, on runways, on the diving board, or platforms.
Glassware and similar material with a tendency to shatter on impact is not allowed in the pool enclosure area.
Domestic animals are not permitted in the pool enclosure, showers, or dressing rooms.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The water temperature in a pool must not be more than 104 degrees Fahrenheit.
Each pool must have the testing equipment specified in this subpart:
a DPD (Diethyl-P-Phenylene Diamine) test kit to measure the concentration of disinfectant in water, accurate within 0.1 parts per million;
When in use, a pool must be continuously disinfected with a chemical that imparts an easily measured, free available residual.
When chlorine is used, a free chlorine residual of at least 1.0 parts per million must be maintained throughout the pool.
When bromine is used, a bromine residual of at least 2.0 parts per million must be maintained throughout the pool.
The disinfectant concentration in an operating pool must not exceed ten parts per million for chlorine and 20 parts per million for bromine.
If the concentration of combined chlorine residual exceeds 0.5 parts per million, the pool must be superchlorinated or treated to reduce the concentration of the combined chlorine residual to not exceed 0.5 parts per million.
The disinfectant residual in a spa pool must be at least 2.0 parts per million for free chlorine and 4.0 parts per million for bromine throughout the pool when in use.
Water in the pool must be maintained with a pH of not less than 7.2 and not more than 7.8.
The alkalinity of the water in the pool must be at least 50 parts per million.
Whenever the pool is open for use, the pool water must be clear enough so the bottom drain is easily visible.
Chemicals used to control water quality must not impart toxic properties to the water. All containers used for chemicals must be kept in a secure location, inaccessible to pool users, and properly labeled and stored according to the manufacturer's instructions.
When bacteriological sampling is done, no sample collected may:
indicate the presence of total coliform organisms in a 100 milliliter sample by any of the following methods:
the Minimal Medium ONPG-MUG test described in Code of Federal Regulations, title 40, part 141.
All samples must be collected, dechlorinated, and examined according to the American Public Health Association's "Standard Methods for the Examination of Water and Wastewater."
Where sampling indicates that the standards in subpart 9 are exceeded, the pool must be treated to effectively reduce biological concentration to a complying level.
19 SR 1419; 19 SR 1637; 40 SR 1646; 46 SR 175
October 11, 2021
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The minimum depth of water in a public pool must be three feet. The maximum depth at the shallow end of the pool must not exceed three feet six inches.
The requirements in subpart 1 do not apply to special purpose pools, wading pools, and pools used for supervised competition.
A pool with a zero depth area may be approved by the commissioner if:
there is an effective barrier, such as stanchions and ropes to restrict access from the deck of the pool to the area where the water depth is less than three feet, except on the side of zero depth. The barrier must permit easy removal for emergency access or maintenance.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Visible dirt on the bottom of the pool must be removed every 24 hours or more frequently as needed to eliminate buildup. Visible scum or floating matter on the pool surface must be removed no less than every 24 hours by flushing or other effective means.
A vacuum-cleaning system capable of cleaning the entire pool must be provided, except that it is not required for spa pools with less than 75 square feet of water surface.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The water supply serving a pool and all plumbing fixtures, including drinking fountains, lavatories, and showers, must meet the requirements of the commissioner for potable water specified in chapters 4720 and 4725.
All portions of the water distribution system serving the pool and related facilities must be protected against backflow. Water introduced into the pool, either directly or through the recirculation system, must be supplied through an air gap or protected with a suitable backflow preventer as specified in UPC sections 602.0 to 603.5.23.4 as incorporated by reference in part 4714.0050.
19 SR 1419; 19 SR 1637
July 11, 2017
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The sewer system must adequately serve the pool, bathhouse, dressing rooms, and related facilities and must conform to the standards of the commissioner of health and the Minnesota Pollution Control Agency.
There must be no direct physical connection between the sewer system and any drain from the pool or recirculation system.
Any pool, gutter drain, or overflow from the recirculation system when discharged to a sewer system, storm drain, or other complying natural drainage course must discharge through a complying air gap or air break to preclude the backup of sewage or waste into the pool or piping system.
Valves and pumps used for draining the pool must be sized or designed to prevent the surcharging of the sanitary sewer.
Any sanitary sewer serving facilities related to the pool must discharge into the public sewer system.
Where a public sewer system is not available, the connection must be made to a treatment system designed, constructed, installed, and operated according to the requirements of the commissioner of health and the Minnesota Pollution Control Agency.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The pool and all appurtenances must be constructed of materials which:
can be finished in a white or light color.
Wood tank construction and vinyl liner pools are prohibited.
The pool must be designed, installed, operated, and constructed to withstand all anticipated loading for both full and empty conditions.
The owner and the architect, engineer, contractor, or other designer is responsible for the structural stability and safety of the pool design.
A hydrostatic relief valve or an underdrain system must be provided where a high water table may affect the stability of the pool.
The pool's shape must:
ensure that user safety is not impaired. Underwater or overhead projections or obstructions that would endanger user safety or interfere with operation are prohibited.
Corners formed by the intersection of walls and the bottom must be rounded with at least a one-half inch radius.
The slope must conform to the provisions in this subpart.
The slope of the bottom of any part of the pool with a water depth of less than five feet must not be more than one foot in ten feet and must be uniform.
In parts of the pool with a water depth greater than five feet, the slope must not exceed one foot in three feet.
The walls of the pool must be either:
vertical for a distance of three feet below the water level, below which the wall may be curved to the bottom with a radius not greater than the difference between the depth at that point and three feet, provided that vertical is interpreted to permit slopes not greater than one foot, horizontally, for each five feet of depth of sidewall (11 degrees vertical).
A ledge along the pool wall within the pool basin is permitted only if it is a necessary part of the sidewall construction. The ledge must be:
Wading pools must be physically separated from other pools and have a separate recirculation system.
Fountains or similar features require approval by the commissioner and must be located in areas of two feet or less of water depth. They must be designed to preclude climbing.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The depth of the water in the pool must be plainly marked in numbers and letters, be in a color contrasting with the background, and specify the water depth and units in feet and inches. Numerals must be at least four inches high. The water depth must be indicated:
Where a transition to a steeper bottom slope occurs, the transition must be marked on the bottom and walls of the pool by a stripe of dark contrasting color at least six inches wide.
Pools and sections of pools that do not comply with the depth requirements for diving in part 4717.3750 must have:
the words "No Diving" in letters not less than four inches high and of a color contrasting with the background located on the pool deck on all sides of the pool where diving is not permitted and spaced at not more than 25 foot intervals; or
the universal no diving symbol at least four inches high accompanied by the words "No Diving" in letters not less than one-half inch high and of a color contrasting with the background located on the pool deck on all sides of the pool where diving is not permitted and spaced at not more than 25 foot intervals. This provision does not apply to spa pools, wading pools, flume or plunge pools.
The leading edge of stair treads must be marked by a stripe of dark, contrasting color between one-half inch and two inches in width.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
All pools must have a water recirculation system with treatment and filtration equipment consisting of overflow gutters or skimmers, main drains, inlets, pumps, piping, filters, water conditioning, disinfection equipment, and other accessory equipment. The pumps, filter, disinfectant and chemical feeders, and related appurtenances must be kept in operation at all times during the swimming season unless approved by the commissioner.
19 SR 1419; 19 SR 1637
May 11, 2009
The water recirculation system must clarify and disinfect the pool volume of water in six hours or less.
The water recirculation system of a wading pool or a special purpose pool must recirculate a water volume equal to the pool volume in two hours or less.
The recirculation system in a spa pool must recirculate a water volume equal to the pool volume in 30 minutes or less, except that a minimum rate of 35 gallons per minute is required.
The recirculation system of a dedicated plunge pool must recirculate a water volume equal to the total volume of the pool in one hour or less.
19 SR 1419; 19 SR 1637
May 11, 2009
Equipment which is part of the installation or alteration of a pool recirculation system must comply with Standard 50 "Circulation System Components for Swimming Pools, Spas or Hot Tubs" of the NSF International.
The recirculation system must include a strainer to prevent debris such as hair and lint from reaching the pump and filters. The strainer must:
Recirculation system piping must:
A rate-of-flow indicator, reading in gallons per minute, must be installed and located, preferably on the pool return line, so the rate of recirculation and backwash rate are indicated. The indicator must be accurate within ten percent of the true flow and be easy to read.
Pumps must provide the number of turnovers of pool water specified in part 4717.2560.
If the pump or suction piping is located above the overflow level of the pool, the pump must be self-priming. The pump or pumps must be capable of providing flow to backwash filters.
Under normal conditions, the pump or pumps must supply the recirculation rate of flow specified in part 4717.2560 at a dynamic head of at least 50 feet for pressure filters.
Pools equipped with heaters must have a fixed thermometer in the recirculation line to measure the temperature of the water returning to the pool.
Valves must be provided on the main drain and skimmer lines to permit balancing the recirculation flow.
19 SR 1419; 19 SR 1637; 46 SR 175
October 11, 2021
All pools must have an outlet at the deepest point to permit the pool to be completely emptied.
Outlet openings of the grating on the floor of the pool must be at least four times the area of discharge pipe and provide enough area so the velocity of water passing the grate does not exceed 1-1/2 feet per second.
When a single outlet is used, it must be at least 100 square inches in size, or have an antivortex cover.
In pools more than 30 feet wide, multiple outlets must be provided. The outlets must be no more than 30 feet apart, and no more than 15 feet from the side walls.
Water inlets must be located to produce uniform circulation of water and maintain a uniform disinfectant residual throughout the entire pool without the existence of dead spots.
Inlets from the recirculation system must be flush with the pool wall and submerged at least 12 inches below the water level.
Over-the-rim fill spouts are not permitted unless located under a diving board or installed in a manner that does not present any hazard.
Make up water spouts must terminate at least six inches above the fill rim of the pool or surge tank.
Inlets must be directionally adjustable and located so there is complete, uniform circulation of incoming water throughout the pool, a uniform disinfectant residual is maintained at all times, and there are no dead spots.
Each inlet must be adjustable or have an individual gate or similar valve to permit adjustment of water volume to obtain the best circulation.
In a pool with a surface area greater than 1,600 square feet or longer than 60 feet, side inlets must be placed at 15-foot intervals around the entire perimeter.
An engineered, manufactured gutter system with integral supply orifices may be used instead of individual directional inlets.
19 SR 1419; 19 SR 1637
May 11, 2009
Overflow gutters must extend completely around the pool except at steps or recessed ladders.
The gutter must continuously remove 50 percent or more of the recirculated water and return it to the filter.
The gutters, drains, and return piping must be sized to remove overflow water caused by recirculation, displacement, wave action, or other cause produced from maximum pool user load.
The opening into the gutter beneath the coping must not be less than four inches wide. The interior of the gutter must not be less than three inches wide with a depth of at least three inches.
The overflow edge or lip must be rounded and no thicker than 2-1/2 inches for the top two inches.
Outlet fittings must have a clear opening in the grating at least equal to 1-1/2 times the cross sectional area of the outlet pipe.
New overflow gutter system installations must include automatic water level control to provide automatic and continuous skimming during quiescence.
An in-pool surge system may be used only if it is part of an engineered and manufactured gutter system that has surge weirs which provide effective skimming during quiescence.
The total surge capacity of the system must be at least one gallon per square foot of water surface.
If some of the surge capacity is within the gutter system, the system must be able to carry 50 percent of the recirculation flow while maintaining the surge capacity.
Nothing in this part precludes the use of a rollout overflow system or deck level system if proper surge capacity is provided as specified in subpart 2.
19 SR 1419; 19 SR 1637
May 11, 2009
Skimmers are permitted in lieu of a gutter if the suction outlets induce enough motion to the pool water to remove floating oil and waste from the entire pool surface, and the edge of the pool deck provides a handhold for swimmers.
At least one skimming device must be provided for each 400 square feet of water surface area or fraction thereof.
Where two or more skimmers are used, they must not interfere with each other and must ensure skimming of the entire pool surface.
Skimmer piping and other components must be designed for a total capacity of at least 80 percent of the required filter flow of the recirculation system.
The skimmer weir must automatically adjust and operate freely with continuous action to variations in water level over a range of at least four inches.
If skimmer equalizer pipes exist, or are constructed, they must include an ASME/ANSI VGB approved suction fitting or be permanently plugged.
Skimmers must have an easily removable and cleanable basket or screen through which all overflow water passes to trap large solids.
19 SR 1419; 19 SR 1637; 46 SR 175
October 11, 2021
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
A pool must have a disinfectant feeder or feeders that meet the requirements in this part.
Feeders must be sturdy and withstand wear, corrosion, or attack by disinfectant solutions or vapors.
Feeders must not be adversely affected by repeated regular adjustment or other anticipated use.
The design and construction of feeders must preclude stoppage from chemicals intended to be used or foreign materials.
Feeders must incorporate failure-proof features so the disinfectant cannot feed directly into the pool, the pool piping system, water supply system, or pool enclosure under any type of failure of the equipment, or during its maintenance.
Feeders must be able to supply at least the equivalent of one pound of chlorine in eight hours for each 10,000 gallons of pool capacity.
Feeders must have a graduated and clearly marked dose adjustment ranging from full capacity to 25 percent of capacity.
When the disinfectant is introduced at the suction side of the pump, a device or method to prevent air lock of the pump or recirculation system must be provided.
19 SR 1419; 19 SR 1637
May 11, 2009
Equipment and piping used to apply chemicals to the water must be sized, designed, and of material that does not clog and is easily cleaned. Material must be resistant to the action of the chemicals used.
Protective equipment recommended by the chemical manufacturer as necessary for the safe handling of any chemicals used must be provided.
19 SR 1419; 19 SR 1637
May 11, 2009
The standards in this part apply when compressed gas chlorine is used. The gas chlorine and chlorinating equipment must be in:
When a room is used, it must comply with the provisions in this subpart.
The room must have a ventilating fan with a capacity to provide one complete air change per minute when the room is occupied.
Separate switches for the fan and lights must be located outside the room. Outside switches must be protected from vandalism. A signal light indicating fan operation must be provided at each entrance when the fan can be controlled from more than one point.
The ventilating fan must take suction near the floor as far as practical from the door and air inlet, with the point of discharge located so as not to contaminate air inlets to any rooms or structures.
When present, floor drains must discharge to the outside of the building and must not be connected to other internal or external drainage systems.
The door of a room or enclosure must be labeled "DANGER - GAS CHLORINE" in letters at least four inches high.
All openings between a chlorine room or enclosure and other enclosed space must be sealed.
Vents from feeders and storage rooms or enclosures must discharge to the outside atmosphere, above grade.
Chlorinating equipment must be capable of withstanding wear without developing leaks.
A valve stem wrench must be maintained on the chlorine cylinder so the supply can be shut off quickly in an emergency.
The valve protection hood must be kept in place except when the cylinder is connected to the system.
The chlorine feeding device must be designed so that during accidents or interruptions of the water supply, leaking chlorine gas is conducted to the out-of-doors.
The chlorinator must be a vacuum-operated solution-feed type, capable of delivering chlorine at its maximum rate without releasing chlorine gas to the atmosphere.
Chlorinators must be designed to prevent the backflow of water into the chlorine solution container.
Respiratory protection equipment, meeting the requirements of the National Institute for Occupational Safety and Health (NIOSH) or the United States Bureau of Mines for chlorine use must be available where chlorine gas is handled. The respiratory protection equipment must be stored at a convenient location, in a closed cabinet accessible without a key, but not inside any room where chlorine is used or stored.
The respirators must use compressed air, have at least a 30-minute capacity, and be compatible with or exactly the same as the respirators used by the fire or emergency rescue department responsible for the pool facility, or be a canister type gas mask with full face mask and replacement canisters provided.
A record of use and inspection must be kept to ensure that the respirators will be serviceable when needed.
A bottle of ammonium hydroxide, 56 percent ammonia solution, or a comparable solution recommended by the chlorine supplier, must be available for chlorine leak detection.
Where ton chlorine containers are used, an emergency leak repair kit recommended by the Chlorine Institute, Inc., 2001 "L" Street NW, Washington, D.C. 20036, must be provided.
Where an automatic leak detector is provided, it must be equipped with both an audible alarm and a visual warning sign.
Installation of chlorinator equipment and its operation must be carried on by and under the supervision of personnel trained by the manufacturer or supplier for the installation and operation of such equipment.
19 SR 1419; 19 SR 1637
May 11, 2009
When hypochlorite solution is fed through hypochlorinating equipment:
the feed must be continuous under all conditions of pressure in the circulating system and feed without artificial constriction of the pump suction line, whether or not the pump suction line is under vacuum or pressure head;
positive features must be designed to prevent backflow from the recirculation system to the solution container and reduce to a minimum the entry into the pool of free calcium released from calcium hypochlorite; and
for aboveground installations, means must be provided to prevent siphoning of hypochlorite solution when the recirculation pump and hypochlorinator are both turned off.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
An erosion feeder must:
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The requirements in this part apply to vacuum and pressure sand filters.
Pressure sand filters must filter at a maximum rate of three gallons per minute per square foot of bed area at the time of maximum head loss with enough area to meet the rate of flow specified in part 4717.2560.
The filtration rate for high-rate sand filters and vacuum sand filters must not exceed 20 gallons per minute per square foot of bed area.
Filter material must be screened, sharp filter sand sized between 0.4 and 0.55 millimeters with a uniformity coefficient not exceeding 1.75. Anthracite sized between 0.6 and 0.8 millimeters with a uniformity coefficient not exceeding 1.8, may be used instead of sand.
The filter material must be at least 20 inches deep for standard pressure sand filters and at least 12 inches deep for high-rate sand filters.
The filter material must be supported by at least ten inches of graded filter gravel. The gravel must distribute water uniformly during filtration and backwashing.
A reduction in depth or an elimination of gravel is permitted when equivalent performance and service is demonstrated through compliance with NSF International Standard 50.
The underdrain system must be corrosion-resistant, enduring, and provide even collection and distribution of the flow during filtration and backwashing. Orifices and other openings must maintain constant area.
Freeboard provided between the upper surface of the filter media and the lowest portion of the pipes or drains which serve as overflows during backwashing must be designed to prevent loss of filter material.
The filter system must have influent and effluent pressure gauges or a filter-mounted pressure gauge, backwash sight glass on the waste discharge line, and an air-relief valve at or near the high point of the filter. The filter system must have valves and piping that permit:
individual backwashing of filters to waste at a rate of not less than 15 gallons per minute per square foot of filter area;
Each pressure filter tank must have an access opening to permit maintenance.
Devices with dosage control features must be provided if coagulants are added ahead of filters.
On pressure filters, the tank and integral parts must have a pressure safety factor of four based on the maximum shutoff head of the pump. For design purposes, the shutoff head must in no case be considered less than 50 pounds per square inch.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The filter area for a diatomaceous earth filter must meet the design pump capacity as required by this part. Where fabric is used, the filter area is determined by the surfaces created by septum supports with no allowance for areas of impaired filtration such as broad supports, folds, or portions which may bridge.
The rate of filtration must not be greater than two gallons per minute per square foot of filter area without continuous body feed and no greater than 2.5 gallons per minute per square foot with continuous body feed.
If a body feeder is used, it must be accurate within ten percent and capable of continually feeding within a calibrated range adjustable from two to six parts per million at the capacity of the recirculation pump. The feeding of diatomaceous earth through skimmers is prohibited.
The filter and all component parts must withstand normal continuous use without significant deformation, deterioration, corrosion, or wear which adversely affects filter operation. The filter design, construction, or other provision must preclude introduction of filter aid into the pool during precoating operations.
Where dissimilar metals which may set up galvanic electric currents are used in the filters, provision must be made to resist electrolytic corrosion.
The filter and surrounding space must permit removal, replacement of any part, and maintenance.
The filter must be cleaned by backwashing, air pump assist backwashing, mechanical or manual spray wash, or agitation.
The tank containing the filter elements must be constructed of steel, plastic, or another material resistant to corrosion, with or without coating.
Pressure filters must be designed for a minimum working pressure of 50 pounds per square inch with a four-to-one safety factor.
Vacuum filters must withstand the pressure developed by the weight of the water contained therein with a safety factor of 1.5.
Closed vacuum filters must withstand crushing pressure developed under a vacuum of 25 inches of mercury with a safety factor of 1.5.
The septa or elements which support the filter-aid must be corrosion-resistant. The septa must resist rupture under conditions of maximum differential pressure between influent and effluent developed by the circulating pump, and resist stress developed by cleaning.
The filter plant must have pressure, vacuum, or compound gauges to indicate the condition of the filter. In vacuum filters where the circulating pump is two horsepower or higher, an adjustable high vacuum automatic shutoff must be provided to prevent damage to the pump by cavitation.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Surface-type cartridge filters must be sized for a maximum filtration rate of 0.375 gallons per minute per square foot. An effluent pressure gauge and an air relief valve must be provided. A spare set of cartridges must be provided and available at all times.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Steps or ladders must be provided at the shallow end of the pool if the vertical distance from the bottom of the pool to the deck or walk is over two feet. Recessed steps or ladders must be provided at the deep end of the pool. If the pool is over 30 feet wide, steps or ladders must be installed on each side.
Steps leading into the pool must be of nonslip material, have a minimum tread of 12 inches, and have a maximum rise or height of ten inches.
There must be no abrupt drop-off or submerged projections into the pool, unless guarded by handrails.
At least two rails must be provided when the steps are over six feet wide or an additional railing is needed to define the location of the steps.
If steps are inserted in the walls or if stepholes are provided, they must be easily cleaned and drain into the pool to prevent the accumulation of dirt. Stepholes must have a minimum tread of five inches and a minimum width of 14 inches.
Pool ladders must be corrosion-resistant and equipped with nonslip treads.
There must be a clearance of not more than five inches nor less than three inches between any ladder and the pool wall.
When stepholes or ladders are provided in the pool, handrails must be provided that extend over the coping or edge of the deck.
All pools, except wading pools and spa pools, must have a continuous handhold along the pool edge.
Where bull-nosed coping is used, it must not be over 2-1/2 inches thick for the outer two inches.
If brick coping is used, it must be completely rounded on the pool side, overhang the pool wall 1-1/2 inches, and slope away from the pool at least one-half inch over the length of the brick.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
A continuous deck, free from fixed obstruction, at least five feet wide, must extend completely around the pool. The deck must be sloped away from the pool to drain at a grade of one-fourth inch per lineal foot. The deck must have a nonslip, nonabsorbent surface.
Deck drains connected to the recirculation system or gutters are prohibited for new installations.
Carpeting must not be used within ten feet of the pool unless it is outside the required deck area and separated from the deck by an effective access barrier. In deck areas where carpeting is contiguous to the deck area, water must be conveyed away from the carpeted area.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Lighting must meet the criteria in this part.
Light must be located to provide illumination so all portions of the pool, including the bottom, may be seen without glare.
Area lighting must provide at least ten footcandles of illumination at all locations on the pool surface and on any deck within five feet of the pool whenever the pool is in use.
A pool used for education, training, or competition must have at least 30 footcandles of illumination on the pool surface and on any deck within five feet of the pool.
All indoor pools, dressing rooms, shower rooms, and toilet space must be ventilated by mechanical means.
All electrical installations must conform with the standards of the Board of Electricity effective at the time of installation.
19 SR 1419; 19 SR 1637; 46 SR 175
October 11, 2021
Starting blocks or starting platforms located at any pool area with a water depth of less than five feet must be removed when the pool is used for other than supervised competitive swimming or training for competitive swimming. For installations after January 1, 1995, all starting blocks or starting platforms must be positioned at a water depth of five feet or greater.
All play equipment at a pool must be specifically designed for pool use and installed in accordance with the safe use parameters specified by the manufacturer and the requirements of the commissioner. All slides used at a pool must meet the requirements specified in part 4717.3870.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
When dressing rooms are provided for both sexes, they must be separated by a tight partition and be designated for men or women.
Floors and wet paths between showers and the pool must have a smooth, nonslip surface, impervious to moisture, and sloped to a drain.
The junctions between walls and floors must be coved or provided with a sealed, easily cleaned joint.
Lockers must be set either on solid masonry bases four inches high or on legs with the bottom of the locker at least ten inches above the floor. Lockers must be vented.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Toilets, showers, and dressing rooms must be conveniently available to pool patrons.
Toilets, showers, and dressing rooms may be in a nearby toiletroom, locker room, or, if conveniently available, within the living units of an apartment building, hotel, or similar occupancy.
Toilet, shower, lavatory, and locker and other ancillary facilities must be maintained in a sanitary condition to preclude the possibility of spreading pathogens to the pool.
When toilet facilities are accessible to pool patrons in the pool area, each toilet facility must include showers which permit nude showering within each toilet facility.
At least one shower must be provided which is conveniently located to permit a shower before entering any pool when sauna or exercise facilities are provided.
Toilet, handwashing, and shower facilities must be provided according to the following schedule.
First 300 males | First 300 females | Additional males over 300 | Additional females over 300 | |
Water closets | 1/100 | 1/50 | 1/200 | 1/100 |
Urinals | 1/100 | -- | 1/200 | -- |
Lavatories | 1/100 | 1/100 | 1/200 | 1/200 |
Showers | 1/50 | 1/50 | 1/50 | 1/50 |
Additional sanitation fixtures must be provided for pool facilities with extensive deck areas or facilities that provide other functions in accordance with the sanitation fixture requirements in the State Building Code.
Showers must be supplied with water at a temperature of at least 90 degrees Fahrenheit at a rate of at least 2.0 gallons per minute. Thermostatic, tempering, or mixing valves must be installed if necessary to prevent water temperatures in excess of 130 degrees.
Pool users leaving the dressing room must pass the showers last in route to the pool.
The floor finish between the toilet and shower areas and the pool must be nonslip and nonabsorbent.
On-site showers are not required for freestanding wading pools if a free chlorine residual of at least two parts per million is maintained in the pool and the owner of the pool requests that on-site showers not be required.
Lighting for toilet, shower, and locker facilities must provide at least ten footcandles illumination measured at floor level.
19 SR 1419; 19 SR 1637
October 3, 2013
Drinking fountains must be provided in the pool area for pools over 1,600 square feet.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
The dimensions of the pool and appurtenances in a diving area must meet the standards in this part.
There must be a completely unobstructed clear distance of 16 feet above the diving board measured from the center of the front end of the board. This area must extend at least eight feet behind, eight feet to each side, and 16 feet ahead of the measuring point.
Pools used for competitive diving must provide pool depths compatible with the level of competition anticipated.
Diving is not permitted, except in areas which conform to the minimum dimensions specified in this part.
The dimensions of the diving area in all pools must conform to the minimum dimensions specified in this part.
Lengths | |||||
Height of Diving Board | Water Depths | Minimum Overhang | Length of Diving Well | Run-out | |
H | Do | D1 | Oh | L1 | L2 |
Deck Level or no board | 6 ft. | 8.5 ft. | 3 ft. | 12 ft. | 10.5 ft. |
1 m | 6 ft. | 10 ft. | 5 ft. | 12 ft. | 15 ft. |
3 m | 6 ft. | 12 ft. | 5 ft. | 13 ft. | 21 ft. |
Clearances | ||||
Height of Diving Board | Water Depths | Adjacent Board's Center-to-Center | Center of Board to Sidewall | |
H | Do | D1 | ||
Deck Level or no board | 6 ft. | 8.5 ft. | 10 ft. | 10 ft. |
1 m | 6 ft. | 10 ft. | 10 ft. | 10 ft. |
3 m | 6 ft. | 12 ft. | 10 ft. | 12 ft. |
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Spa pools must comply with parts 4717.0150 to 4717.3975, except as modified in this part.
The recirculation system must recirculate a water volume equal to the pool volume in 30 minutes or less, except that a minimum rate of 35 gallons per minute is required.
The agitation system must have a separate pump. If sidewall suction fittings are used, at least two inlets, remotely located, must be provided.
The agitation system must be controlled by a timer with the control switch accessible to pool users but at least five feet from the pool. The maximum time setting must be 15 minutes.
Access to a spa pool must be provided according to this subpart.
Access to the pool must be provided by an unobstructed deck, at the pool elevation, which extends at least five feet from the pool around the entire perimeter.
Where a deck cannot be provided as specified in item A, a five-foot wide deck at the pool elevation must extend along at least 25 percent of the pool perimeter. The remaining perimeter must be one foot or less to a wall, partition, or other effective barrier to restrict access. The deck must provide complete and unobstructed access to the steps in the pool.
The requirements for steps in this subpart apply to spa pools.
The disinfection residual must be maintained in accordance with part 4717.1750, subpart 4.
In addition to the signs required in parts 4717.1050, 4717.1350, and 4717.1650, signs with the warnings in items A to C must be posted and plainly visible in the spa pool area.
Pregnant women, small children, or persons with heart disease, diabetes, high blood pressure, or low blood pressure should not enter the spa except under advice of a physician.
19 SR 1419; 19 SR 1637; 46 SR 175
October 11, 2021
All slides used at a pool must be specifically designed and intended for use with a pool, and for use as a slide.
Standard pool slides must meet the Consumer Product Safety Commission Standard "Safety Standard for Swimming Pool Slides," Code of Federal Regulations, title 16, part 1207, as amended through December 18, 1978.
Slides for use by children in wading pools must be designated by the manufacturer for use in 24 inches or less of water, and installed accordingly.
A slide other than a standard pool slide that discharges to a pool with a drop of more than two inches to the water surface must meet the requirements in this subpart.
At least one attendant must be continuously present observing the slide and controlling its use.
Slide entry areas must be designed so the rider is able to properly enter and position before sliding down the chute. This area must be a platform or flat portion of the chute with assist bars.
Handrails must be present on both sides of the ladder or steps. Platforms and landings must have 42-inch high guardrails, with at least one intermediate-height rail.
A landing area must be provided that extends five feet on either side of the center line of the slide and from the back wall to 20 feet in front of the slide terminus.
The landing area must not infringe on the required landing area for any other slide or diving equipment.
A slide mounted in a separate diving area may be allowed to use the separate diving area if access to the diving well is restricted to patrons using the slide and diving equipment.
The terminus of the slide chute must extend beyond the pool wall and be so oriented that the landing area in front of the slide does not interfere with the landing area of another slide or other pool equipment.
The maximum angle of the slide runway at the exit must be between zero degrees and 11 degrees, measured downward from horizontal.
The area from the slide terminus outward to six feet in front of the slide terminus must have a depth as specified in this item.
If the depth of the terminus area is five feet or less, the bottom of this area must have a maximum slope of one inch in 12 inches and the slide must be located at least five feet from any change to steeper slope of the pool bottom.
If the slide exit is 12 inches or less above the water, the water depth from the slide terminus to six feet in front of the terminus must be in the four to five feet range.
If the slide exit is more than 12 inches above the water, the water depth from the slide terminus to six feet in front of the terminus must be at least eight feet.
If water is pumped from a pool to the slide, the pump intake must be enclosed or constructed to prevent injury or entrapment of pool users. Intake velocity must not exceed 1-1/2 feet per second.
Slides must be located and constructed to allow easy supervision. When a slide is not supervised, or not open for use, it must be secured to prevent access.
The slide must have posted a set of rules that include the requirements in subitems (1) to (6).
19 SR 1419; 19 SR 1637
October 3, 2013
A flume water slide facility must comply with parts 4717.0150 to 4717.3975, except as modified in this part.
When the flume is in use, at least one attendant must be continuously present, observing the flume and controlling its use.
A flume must discharge to a dedicated plunge pool or dedicated area of a pool with a separate ladder or stairs.
The pool's operating water depth at the end of the flume must be no less than three feet and no more than three feet six inches.
The depth specified in item A must be maintained in front of the flume's discharge point for a distance of at least ten feet.
The exit end of the flume must be perpendicular to the plunge pool wall for a distance of at least ten feet.
The flume must terminate no more than six inches below the pool operating water surface level and no more than two inches above the pool operating water surface level.
The side of the exit end of the flume must be at least four feet from the side of the pool wall.
The distance between a flume exit end and the opposite side of the pool must be at least 20 feet.
Water pumped to the top of a flume must be pumped from a reservoir connected to the pool.
Where any entrance to a pump reservoir presents an underwater obstruction, patron access to that area must be prevented.
Each flume pump discharge pipe must have a check valve. The volume of water in the pool during use and shutdown of any flume pump must permit proper operation of the recirculation system.
The recirculation system for a dedicated plunge pool must recirculate the water in accordance with part 4717.2560, subpart 4.
Walkways from the pool deck to the top of the flume or tower, the tower stairs, and platforms must have finished surfaces which meet the requirements for decks in part 4717.3350.
Fencing complying with part 4717.1550 or other enclosure must encompass the pool deck, walkways, and flume access.
Flume design plans must include:
all related construction details.
Flume support and tower structure plans must be certified by a registered engineer or approved by a local building official for structural integrity.
A legible sign with the warnings in this subpart must be located at the entrance to each flume slide.
19 SR 1419; 19 SR 1637
May 11, 2009
[Repealed, 19 SR 1419; 19 SR 1637]
May 11, 2009
Wave pools must comply with parts 4717.0150 to 4717.3975, except as modified in this part.
When the wave pool is in use:
the minimum number of lifeguards who must be continuously present must be one for every 2,000 square feet of pool surface water where the pool depth is greater than two feet; and
where the design, configuration, or operation requires additional lifeguards to provide complete observation of the entire pool they must be provided in addition to those required in item A.
Water depth may reduce to zero at the shallow end of the pool to allow for dissipation of the waves.
In addition to the fencing required in part 4717.1550, a safety barrier of stanchions and ropes or a similar barrier at least 42 inches high must be located to prevent pool patrons from entering the pool at any location other than at the zero water depth end. The barrier must have at least one intermediate height rope.
An emergency shut off for wave generation must be provided at every lifeguard chair or station.
The wave generating equipment must not be capable of producing waves that could cause pool users to have contact with the pool bottom in a manner which may cause injury.
Overflow gutters may be omitted along the side of a pool with the wave generating equipment.
If overflow gutters are not provided on the pool side where the wave generating equipment is located, effective skimming devices are required and must be designed and maintained to function continuously during all periods when waves are not generated.
Overflow gutters are required on the sides of the pool where the wave generating equipment is not installed.
Deck areas accessible to pool users may be omitted along the side of the pool with the wave generating equipment.
The recirculation system must operate at a rate equivalent to recirculating the total volume of water in the pool in four hours or less. A system of bottom inlets must be provided in the shallow end.
19 SR 1419; 19 SR 1637
May 11, 2009
When any of the conditions in items A to E are found, a public pool must be immediately closed to use when so ordered by the commissioner. The owner of the pool or the owner's agent must place a sign at the entrance to the pool indicating that the pool is closed. The pool must remain closed until the condition is corrected and approval to reopen is granted by the commissioner. A pool must be closed when:
19 SR 1419; 19 SR 1637; 46 SR 175
October 11, 2021
The commissioner shall grant a variance to parts 4717.0100 to 4717.3950 only according to the procedures and criteria specified in parts 4717.7000 to 4717.7050.
19 SR 1419; 19 SR 1637
May 11, 2009
A self-priming pump, suitable for pumping raw sewage or other wastes, and easily serviceable in the event of clogging shall be provided for the on-land disposition of sewage or other wastes from watercraft or other marine conveyance equipped with a marine toilet and retention device. Head characteristics and capacity shall be based on installation needs for the site; however, as a minimum the pump shall be capable of lifting sewage or other wastes 12 feet. The pump may be either fixed in position or portable mounted.
MS s 144.12
May 11, 2009
The suction hose shall be pliable, noncollapsible, nonkinking, and a minimum of 15 feet in length. It shall have a smooth interior. A quick-connect drip-proof connector shall be fitted to the end of the hose that is attached to the boat piping outlet. Such connector should be capable of a friction fit in the inside diameter of a 1-1/2-inch Schedule 40 pipe.
MS s 144.12
May 11, 2009
Flexible hose, compatible with the pump characteristics, shall be used. The discharge hose and suction hose of part 4717.4100 shall be labeled and color-coded brown. All permanent piping shall conform to the Minnesota Plumbing Code, chapter 4714.
MS s 144.12
July 11, 2017
When connection to a public sanitary sewer is available, the disposal piping shall be designed to discharge thereto.
When a public sewer is not available, a private sewage disposal system installed in compliance with applicable state standards shall be provided unless adequate private treatment and disposal systems are already available. The sewage disposal system may be either a septic tank-soil absorption system or a holding tank.
MS s 144.12
May 11, 2009
The on-land disposal facility shall be served by a water supply piping system to permit flushing of the facilities serviced. If a potable water supply is the source of flushing, the distribution piping shall be protected from back-siphonage and back-pressure, labeled, and color-coded brown from the back-siphonage, back-pressure device to the end of the hose. A separate hose shall be provided for filling the drinking water system of the watercraft or other marine conveyance. That hose shall be labeled and color-coded blue.
MS s 144.12
May 11, 2009
Two sets of plans and specifications for the proposed construction of new, or modification of existing on-land disposal facilities for the receipt of sewage or other wastes from watercraft or other marine conveyances equipped with marine toilets and retention devices shall be submitted to the Minnesota Department of Health. The proposed modification or construction of the on land disposal facilities shall not commence until the plans and specifications are approved, in writing, by the Department of Health. If the disposal system is designed to discharge an effluent to the waters of the state, or involves a sewer extension from a municipal sewer system, plan approval and a permit shall also be obtained from the Minnesota Pollution Control Agency.
At a minimum, plans and specifications shall cover in detail the materials to be used, the pump characteristics, and the water supply system. Where applicable, the connection to the public sewer or the private disposal system, the size and construction details of the septic or holding tank, results of soil percolation tests and soil borings and the construction details of the soil absorption system shall be included. Location of all wells within 100 feet of the absorption system, the surface water high water level and the general topography of the area shall be shown on the plans.
Plans and specifications will not be reviewed for approval until they are submitted in sufficient detail to permit proper evaluation for compliance with Minnesota Statutes, sections 86B.325; 86B.401, subdivision 1, paragraph (c); and 86B.535; and these and all other applicable rules. The plan approval required by this section shall be in addition to any other permit, approval, or license required by federal, state, or local law.
MS s 144.12
May 11, 2009
[Repealed, 14 SR 1874]
May 11, 2009
[Repealed, 14 SR 1874]
May 11, 2009
[Repealed, 14 SR 1874]
May 11, 2009
[Repealed, 14 SR 1874]
May 11, 2009
[Repealed, 14 SR 1874]
May 11, 2009
[Repealed, 14 SR 1874]
May 11, 2009
[Repealed, 14 SR 1874]
May 11, 2009
[Repealed, 14 SR 1874]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
[Repealed, 15 SR 1842]
May 11, 2009
A party may ask the commissioner of health to grant a variance from the following items:
asbestos abatement, part 4620.3710, item A, and, where space limitations prevent compliance with the specified requirements or where compliance with the specified requirements would create a greater hazard, parts 4620.3566, 4620.3567, 4620.3568, subparts 1 to 4, 4620.3569, 4620.3571, subparts 1 and 2, and 4620.3575, subpart 3;
lodging establishments, parts 4625.0400 to 4625.0600; 4625.0900; 4625.1200 to 4625.1600; 4625.2000, except the last sentence; and 4625.2200;
manufactured home parks and recreational camping areas, parts 4630.0400; 4630.0600, subparts 2 to 4; and 4630.0900 to 4630.1700;
general requirements for construction of surface water and groundwater under the direct influence of surface water treatment facilities, parts 4720.3920 to 4720.3965;
The procedures in this subpart apply to a request for a variance of the rules specified in subpart 1. Additional procedures may be specified in the rules listed in subpart 1 which also must be complied with. The party requesting the variance must submit the variance request in writing to the commissioner of health along with any applicable fee. A request must contain:
the alternative measures that will be taken to assure a comparable degree of protection to health or the environment if a variance is granted;
a statement that the party applying for the variance will comply with the terms of the variance, if granted; and
other relevant information the commissioner determines necessary to properly evaluate the request for the variance.
The applicant for a variance must be the party to whom the rule specified in subpart 1 applies.
MS s 14.05; 14.388; 31.101; 31.11; 103I.101; 103I.221; 103I.301; 103I.621; 144.05; 144.08; 144.12; 144.1202; 144.1203; 144.123; 144.383; 144.4961; 144.9508; 145A.02; 157.01; 157.011; 157.04; 157.08; 157.09; 157.13; 326.70 to 326.81
15 SR 1597; 17 SR 2773; 19 SR 1419; 19 SR 1637; 20 SR 2765; 22 SR 314; 22 SR 668; 23 SR 519; 23 SR 1591; 26 SR 31; 28 SR 147; 29 SR 531; L 2007 c 140 art 13 s 3; 33 SR 1771; L 2015 c 21 art 1 s 109; 43 SR 687; 44 SR 239
November 26, 2019
The commissioner may grant a variance if:
the variance will have no potential adverse effect on public health, safety, or the environment;
the alternative measures to be taken, if any, are equivalent to or superior to those prescribed in the rule;
In granting a variance the commissioner may attach conditions the commissioner determines are needed to protect public health, safety, or the environment.
MS s 14.05
15 SR 1597
May 11, 2009
The commissioner of health shall notify the party in writing of the commissioner's decision to grant or deny the variance. If a variance is granted, the notification must specify the period of time for which the variance will be effective and the alternative measures or conditions, if any, the applicant must meet. If a variance is denied, the commissioner of health shall specify the reasons for the denial.
MS s 14.05
15 SR 1597
May 11, 2009
Alternative measures or conditions attached to a variance have the force and effect of the applicable rule. If the party violates the alternative measures or conditions attached to the variance, the party is subject to the enforcement actions and penalties provided in the applicable law or rule. The party to whom a variance has been issued must notify the commissioner of health in writing within 30 days of any material change in the conditions upon which the variance was granted.
MS s 14.05
15 SR 1597
May 11, 2009
A request for the renewal of a variance must be submitted to the commissioner of health in writing 30 days before its expiration date. Renewal requests must contain the information specified in part 4717.7000, subpart 2. The commissioner shall renew a variance if the party continues to satisfy the criteria contained in part 4717.7010 and demonstrates compliance with the alternative measures or conditions imposed at the time the original variance was approved. This provision does not apply if there has been any material change in the conditions upon which the variance was granted.
MS s 14.05
15 SR 1597
May 11, 2009
The commissioner shall deny, revoke, or refuse to renew a variance if the commissioner determines that the criteria in part 4717.7010 are not met.
A party may appeal the denial, revocation, or refusal to renew a variance by requesting, in writing, a contested case hearing under the Administrative Procedure Act, Minnesota Statutes, chapter 14, within 30 days of receipt of the notice to deny, revoke, or refuse to renew the variance.
MS s 14.05
15 SR 1597
September 29, 2009
[Repealed, 33 SR 1792]
September 29, 2009
September 29, 2009
[Repealed, 33 SR 1792]
September 29, 2009
[Repealed, 33 SR 1792]
September 29, 2009
[Repealed, 33 SR 1792]
September 29, 2009
This part contains the table of the health risk limits.
CAS RN | RfD* (milligrams per kilogram per day) | Slope factor* (the inverse of milligrams per kilogram per day) | Health Risk Limit (micrograms per liter) |
Allyl chloride (3 chloropropene):
107-05-1 | 0.05 (C) | -- | 30 |
Butylphthalyl butylglycolate (BPBG):
85-70-1 | 1 | -- | 7,000 |
1,2-Dibromoethane (Ethylene dibromide, EDB):
106-93-4 | -- | 85 | 0.004 |
p,p'-Dichlorodiphenyl dichloroethane (DDD):
72-54-8 | -- | 0.24 | 1 |
p,p'-Dichlorodiphenyldichloroethylene (DDE):
72-55-9 | -- | 0.34 | 1 |
p,p'-Dichlorodiphenyltrichloroethane (DDT):
50-29-3 | -- | 0.34 | 1 |
2-Methyl-4-chlorophenoxyacetic acid (MCPA):
94-74-6 | 0.0005 | -- | 3 |
Methyl ethyl ketone (MEK, 2-butanone):
78-93-3 | 0.6 | -- | 4,000 |
Polychlorinated biphenyls (PCBs):
1336-36-3 | -- | 7.7 | .04 |
2,4,5-Trichlorophenoxyacetic acid (2,4,5-T):
93-76-5 | 0.01 | -- | 70 |
1,1,2-Trichloro-1,2,2-trifluoroethane:
76-13-1 | 30 | -- | 200,000 |
For purposes of this part:
* Substances or chemicals that have an RfD or slope factor annotated with a (C) are classified by the United States Environmental Protection Agency as possible human carcinogens.
18 SR 1340; 19 SR 1191; 32 SR 373; 35 SR 1395; 38 SR 397; 40 SR 689; 43 SR 262
September 12, 2018
[Repealed, 33 SR 1792]
May 11, 2009
[Repealed, 33 SR 1792]
May 11, 2009
[Repealed, 33 SR 1792]
May 11, 2009
[Repealed, 33 SR 1792]
May 11, 2009
[Repealed, 33 SR 1792]
May 11, 2009
The purpose of parts 4717.7810 to 4717.7900 is to establish health risk limits (HRLs) for substances found to degrade Minnesota groundwater.
As provided by Minnesota Statutes, sections 103H.005, subdivision 3, and 103H.201, subdivision 1, HRLs are derived as human health-based groundwater standards based on cancer or noncancer effects from consumption and federal maximum contaminant levels incorporated by reference as required by Laws 2007, chapter 147, article 17, section 2.
Health risk limits are for use by public agencies and private entities in Minnesota in determining whether groundwater, impacted by human activity, is subject to regulatory or advisory actions based on human health concerns. HRLs specify a minimum level of quality for water used for human consumption, such as ingestion of water, and do not imply that allowing degradation of water supplies to HRL levels is acceptable.
MS s 103H.201
33 SR 1792
May 11, 2009
For the purposes of parts 4717.7810 to 4717.7900, the terms in this part have the meanings given them.
"AFlifetime" or "lifetime adjustment factor" is a numerical multiplier used to modify the adult-based cancer slope factor for lifetime exposure based on chemical-specific data.
"ADAFs" or "age-dependent adjustment factors" are the default modifiers to the cancer slope factor that account for the increased susceptibility to cancer from early life exposures to linear carcinogens in the absence of chemical-specific data. For the default derivation of cancer HRLs, the following ADAFs and corresponding age groups are utilized:
ADAF<2=10, for birth until two years of age; ADAF2 to <16=3, for two up to 16 years of age; and ADAF16+=1, for 16 years of age and older.
"Additional lifetime cancer risk" means the probability that daily exposure to a carcinogen over a lifetime may induce cancer. The Department of Health uses an additional cancer risk of 1x10-5 (1 in 100,000) to derive cancer HRLs.
"Carcinogen" means a chemical:
classified as a human carcinogen or a probable human carcinogen according to the "EPA Classification System for Categorizing Weight of Evidence for Carcinogenicity from Human and Animal Studies," the Risk Assessment Guidelines of 1986, United States Environmental Protection Agency, Office of Health and Environmental Assessment (August 1987), which is incorporated by reference;
classified as "carcinogenic to humans" or "likely to be carcinogenic to humans" according to the Final Guidelines for Carcinogenic Risk Assessment, United States Environmental Protection Agency, Office of Research and Development (March 2005), which are incorporated by reference. The guidelines are not subject to frequent change. The final guidelines are available at: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=116283 or through the public library using the Minitex interlibrary loan system; or
classified as a substance known to be a human carcinogen or reasonably anticipated to be a human carcinogen in the Report on Carcinogens, United States Department of Health and Human Services, Public Health Service, National Toxicology Program. This report is incorporated by reference and is subject to frequent change. The report is available at: http://ntp.niehs.nih.gov/go/roc.
"Chemical" includes a single chemical or a defined mixture of two or more chemicals.
The "chemical abstracts service registry number" or "CAS number" means the number assigned to a chemical by the Chemical Abstracts Service, a division of the American Chemical Society, 2540 Olentangy River Road, Box 3012, Columbus, OH 43210-0012. CAS numbers function as unique identifiers for chemicals in part 4717.7860. The Chemical Abstracts Service maintains a database of all CAS numbers at http://www.cas.org.
"Developmental health endpoint" or "developmental" means an adverse effect on the developing organism that may result from parental exposure prior to conception, maternal exposure during prenatal development, or direct exposure postnatally until the time of sexual maturation. Developmental toxicity may be detected at any point in the lifespan of the organism. The major manifestations of developmental toxicity include:
"Duration" means the length of the exposure period under consideration.
For the default derivation of noncancer health risk limits, the following durations are utilized:
subchronic - a period of more than 30 days, up to approximately ten percent of the life span in humans; or
For the default derivation of cancer health risk limits, the durations corresponding to the three age groups associated with the age-dependent adjustments (ADAFs) specified in subpart 3, are utilized:
For the chemical-specific derivation of a noncancer or cancer health risk limit, the duration is based on chemical-specific information regarding the relevant length of exposure.
"Endocrine" or "(E)" means a change in circulating hormone levels or interactions with hormone receptors, regardless of the organ or organ system affected. Endpoints with or without the (E) designation are deemed equivalent, for example, thyroid (E)=thyroid, and shall be included in the same health risk index equation in part 4717.7880.
"Health risk index" is a sum of the quotients calculated by identifying all chemicals that share a common health endpoint and dividing the measured or statistically derived concentration of each chemical by its HRL. The multiple chemical health risk index is compared to the multiple chemical health risk limit, defined in subpart 19 as one, to identify exceedances. Equations to calculate multiple chemical health risk indices are found in parts 4717.7880 and 4717.7890.
"Health risk index endpoint" or "health endpoint" means the general description of toxic effects used to group chemicals for the purpose of calculating a health risk index. Health risk index endpoints or health endpoints for each chemical are listed in part 4717.7860.
"Health risk limit" or "HRL" has the meaning given in Minnesota Statutes, section 103H.005, subdivision 3. An HRL is expressed as µg/L.
"Intake rate" or "IR" means the rate of ingestion of water, or the amount of water, on a per body weight basis, ingested per day, expressed as liters per kilogram body weight per day or L/kg-day. The time-weighted average of the 95th percentile intake rate for the derivation of cancer and noncancer HRLs is calculated for the relevant duration specified in subpart 9.
"Maximum contaminant level" or "MCL" means the maximum permissible level of a contaminant in water that is delivered to any user of a public water system under the Federal Drinking Water Program according to Code of Federal Regulations, title 40, section 141.2.
"Maximum contaminant level-based health risk limit" or "MCL-based HRL" means an MCL that is adopted as an HRL as authorized by Laws 2007, chapter 147, article 17, section 2.
"mg/kg-day" means milligrams of chemical per kilogram of body weight per day.
The "multiple chemical health risk limit" or "multiple chemical HRL" is equal to one. Equations to determine whether the multiple chemical health risk limit has been exceeded are in parts 4717.7880 and 4717.7890.
"Nonlinear carcinogen" means a chemical agent for which, particularly at low doses, the associated cancer risk does not rise in direct proportion to the extent of exposure, and for which a threshold level of exposure exists below which there is no cancer risk. The HRL for a nonlinear carcinogen is based on a reference dose that is lower than the threshold for cancer risk.
"Reference dose" or "RfD" means an estimate of a dose for a given duration to the human population, including susceptible subgroups such as infants, that is likely to be without an appreciable risk of adverse effects during a lifetime. It is derived from a suitable dose level at which there are few or no statistically or biologically significant increases in the frequency or severity of an adverse effect between the dosed population and its associated control group. The RfD includes one or more divisors, applied to the suitable dose level, accounting for: (i) uncertainty in extrapolating from mammalian laboratory animal data to humans; (ii) variation in toxicological sensitivity among individuals in the human population; (iii) uncertainty in extrapolating from effects observed in a short-term study to effects of long-term exposure; (iv) uncertainty in using a study in which health effects were found at all doses tested; and (v) uncertainty associated with deficiencies in the available data. An HRL is not derived if the product of the divisors exceeds 3,000. The RfD is expressed as mg/kg-day.
"Relative source contribution" or "RSC" means the fraction of total exposure to a substance or chemical that is allocated to drinking water. The default RSC is 0.2 for highly volatile chemicals. For other chemicals, the default RSC is 0.5 for acute and short-term HRLs and 0.2 for subchronic or chronic HRLs.
"Slope factor" or "SF" means an upper-bound estimate of risk per increment of dose that can be used to estimate cancer risk probabilities for different exposure levels. A cancer slope factor is expressed as cancer incidence per mg/kg-day. Minnesota Statutes, section 103H.201, subdivision 1, paragraph (d), requires the Department of Health, when deriving cancer HRLs, to use cancer slope factors published by the United States Environmental Protection Agency.
"Toxic effects" means an observable or measurable adverse biological event, or the organ, tissue, or system in which the effect is manifested. The designation of endpoints does not exclude other possible observable and measurable biological events. For the purpose of grouping chemicals and creating a health risk index when multiple chemicals are present, toxic effects may be ascribed to more general health risk index endpoints or health endpoints. Health endpoints are listed in part 4717.7860.
"Volatility" means having a tendency to evaporate. Using Henry's Law constants, chemicals are characterized as nonvolatile or low, moderate, or high volatility as follows:
MS s 103H.201
33 SR 1792
January 4, 2016
This part establishes the method for determining a health risk limit for a toxic effect other than cancer.
The equation for deriving a health risk limit for a toxic effect other than cancer or a maximum contaminant level-based health risk limit is:
RfDduration x RSC x 1,000 | ||
nHRLduration= | _ | |
IRduration |
Where:
nHRLduration is the noncancer health risk limit for a given duration as defined in part 4717.7820, subparts 9, item A, and 13, expressed as µg/L. The HRLs derived for each chemical are listed in part 4717.7860.
RfDduration is the reference dose for a given duration as defined in part 4717.7820, subparts 9, item A, and 21, expressed as mg/kg-day. The RfDs utilized for each chemical are listed in part 4717.7860.
RSC is the relative source contribution factor as defined in part 4717.7820, subpart 22. The RSCs utilized for each chemical are listed in part 4717.7860.
1,000 is a factor used to convert milligrams (mg) to micrograms (µg). There are 1,000 micrograms per milligram.
MS s 103H.201
33 SR 1792
May 11, 2009
This part establishes the methods for determining a health risk limit for cancer.
The equation for deriving the health risk limit for cancer for chemicals other than chemicals identified in subpart 3, or nonlinear carcinogens is:
(1x10-5) x 1,000 | |
cHRL= | _ |
[(SFxADAF<2xIR<2xD<2)+(SFxADAF2 to <16xIR2 to <16xD2 to <16)+(SFxADAF16+xIR16+xD16+)]/70 years |
Where:
SF or slope factor is expressed in units of cancer incidence per mg/kg-day. The SFs utilized for each chemical are listed in part 4717.7860.
ADAF is the age-dependent adjustment factor as defined in part 4717.7820, subpart 3. The ADAFs utilized for each chemical are listed in part 4717.7860.
IRduration is the intake rate for a given duration as defined in part 4717.7820, subpart 14. The IRs utilized for each chemical are listed in part 4717.7860.
D is the duration corresponding to the three age groups birth up to two years of age (two-year duration), two up to 16 years of age (14-year duration), and 16 up to 70 years of age (54-year duration) as defined in part 4717.7820, subpart 9, item B.
70 years is the standard lifetime duration utilized by the United States Environmental Protection Agency in the characterization of lifetime cancer risk.
The Department of Health may depart from the default equation presented in subpart 2 when an adjustment factor is based on chemical-specific information. The equation for deriving the health risk limit for cancer for these chemicals is:
(1x10-5) x 1,000 | ||
cHRL= | _ | |
[SFxAFlifetime x IRlifetime] |
Where:
Units or values for cHRL, (1x10-5), 1,000, and SF are as described in part 4717.7840, subpart 2.
MS s 103H.201
33 SR 1792
May 11, 2009
This part establishes the methods for determining a health risk limit based on a maximum contaminant level.
As authorized by Laws 2007, chapter 147, article 17, section 2, the maximum contaminant levels for the following chemicals are adopted by reference as health risk limits:
33 SR 1792; 40 SR 689
January 4, 2016
This table lists the health risk limits derived from methods specified in parts 4717.7830, 4717.7840, and 4717.7850. For each chemical, this table specifies:
The following explanations in subitems (1) to (3) apply where noted:
The acute HRL value is less than the calculated HRL. To be protective of acute exposures, the HRL is set equal to the acute HRL value.
The short-term HRL value is less than the calculated HRL. To be protective of short-term exposures, the HRL is set equal to the short-term HRL value.
The subchronic HRL value is less than the calculated HRL. To be protective of subchronic exposures, the HRL is set equal to the subchronic HRL value.
CAS number: 83-32-9 | |
Year Adopted: 2018 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 200 | 100 | NA |
RfD (mg/kg-day) | -- | -- | 0.070 | 0.021 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
Endpoints | -- | -- | adrenal, hepatic (liver) system | adrenal, hepatic (liver) system | -- |
CAS number: 103-90-2 | |
Year Adopted: 2015 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 200 | 200 | 200 (2) | 200 (2) | NA |
RfD (mg/kg-day) | 0.25 | 0.25 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | -- |
CAS number: 34256-82-1 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 30 | 30 | 20 | NA |
RfD (mg/kg-day) | -- | 0.016 | 0.012 | 0.0039 | -- |
RSC | -- | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
Endpoints | -- | developmental, hepatic (liver) system, thyroid (E) | hepatic (liver) system, male reproductive system, nervous system, renal (kidney) system | hepatic (liver) system, male reproductive system, nervous system, renal (kidney) system, respiratory system | -- |
CAS number: 187022-11-3 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 500 | 500 | 300 | NA |
RfD (mg/kg-day) | -- | 0.29 | 0.19 | 0.056 | -- |
RSC | -- | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
Endpoints | -- | thyroid (E) | male reproductive system, thyroid (E) | male reproductive system, thyroid (E) | -- |
CAS number: 184992-44-4 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 100 (2) | 90 | NA |
RfD (mg/kg-day) | -- | 0.081 | (2) | 0.019 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | 0.044 | -- |
Endpoints | -- | thyroid (E) | thyroid (E) | thyroid (E) | -- |
CAS number: 67-64-1 | |
Year Adopted: 2011 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 9,000 | 8,000 | 4,000 | NA |
RfD (mg/kg-day) | -- | 5.0 | 3.0 | 0.90 | -- |
RSC | -- | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | 0.043 | -- |
Endpoints | -- | renal (kidney) system | renal (kidney) system, hematological (blood) system | renal (kidney) system, hematological (blood) system | -- |
CAS number: 21145-77-7 or 1506-02-1 | |
Year Adopted: 2013 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 30 | 20 | NA |
RfD (mg/kg-day) | -- | 0.070 | 0.011 | 0.0037 | -- |
RSC | -- | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | 0.043 | -- |
Endpoints | -- | hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | -- |
CAS number: 79-06-1 | |
Year Adopted: 2015 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 7 | 7 (2) | 7 (2) | 0.2 |
RfD (mg/kg-day) | -- | 0.010 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.5 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
Endpoints | -- | developmental, male reproductive system, nervous system | developmental, male reproductive system, nervous system | developmental, male reproductive system, nervous system | cancer |
CAS number: 15972-60-8 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 60 | 9 | NA |
RfD (mg/kg-day) | -- | 0.077 | 0.020 | 0.0020 | -- |
RSC | -- | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
Endpoints | -- | developmental, renal (kidney) system | hematological (blood) system, hepatic (liver) system, renal (kidney) system | hematological (blood) system, hepatic (liver) system, renal (kidney) system | -- |
CAS number: 1912-24-9 | |
Year Adopted: 2009 | |
Volatility: Nonvolatile | |
MCL-based HRL: 3 µg/L |
CAS number: 25057-89-0 | |
Year Adopted: 2015 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 400 | 60 | 50 | 30 | NA |
RfD (mg/kg-day) | 0.22 | 0.033 | 0.020 | 0.0060 | -- |
RSC | 0.5 | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | 0.077 | 0.043 | -- |
Endpoints | developmental, female reproductive system | developmental | hematological (blood) system | thyroid | -- |
CAS number: 71-43-2 | |
Year Adopted: 2009 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 10 | 10 | 3 | 3 (3) | 2 |
RfD (mg/kg-day) | 0.015 | 0.014 | 0.0013 | (3) | -- |
RSC | 0.2 | 0.2 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.055 |
ADAF | -- | -- | -- | -- | 10 (ADAF<2) |
3 (ADAF2 to <16) | |||||
1 (ADAF16+) | |||||
Intake Rate | 0.289 | 0.289 | 0.077 | (3) | 0.137 (<2) |
(L/kg-day) | 0.047 (2 to <16) | ||||
0.039 (16+) | |||||
Endpoints | develop- mental |
hemato- logical (blood) system, immune system |
hemato- logical (blood) system, immune system |
hemato- logical (blood) system, immune system |
cancer |
CAS number: 80-05-7 | |
Year Adopted: 2015 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 20 | 20 (3) | NA |
RfD (mg/kg-day) | -- | 0.16 | 0.0065 | (3) | -- |
RSC | -- | 0.2 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | (3) | -- |
Endpoints | -- | developmental, female reproductive system (E), hepatic (liver) system, male reproductive system (E), renal (kidney) system, thyroid (E) | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
CAS number: 85-68-7 | |
Year Adopted: 2015 | |
Volatility: Low |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 100 | 100 | 100 (2) | 100 (2) | NA |
RfD (mg/kg-day) | 0.15 | 0.15 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | developmental (E) | developmental (E) | developmental (E) | developmental (E) | -- |
CAS number: 7440-43-9 | |
Year Adopted: 2015 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 5 | 1 | 1 | 0.5 | NA |
RfD (mg/kg-day) | 0.0077 | 0.0016 | 0.00044 | 0.00011 | -- |
RSC | 0.2 | 0.2 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | 0.077 | 0.043 | -- |
Endpoints | developmental | developmental, nervous system, renal (kidney) system | developmental, skeletal | renal (kidney) system, skeletal | -- |
CAS number: 298-46-4 | |
Year Adopted: 2013 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 40 | 40 | 40 (2) | 40 (2) | NA |
RfD (mg/kg-day) | 0.013 | 0.013 | (2) | (2) | -- |
RSC | 0.8 | 0.8 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate | 0.289 | 0.289 | (2) | (2) | -- |
(L/kg-day) | |||||
Endpoints | develop- mental, nervous system |
develop- mental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E) |
develop- mental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E) |
develop- mental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E) |
-- |
CAS number: 56-23-5 | |
Year Adopted: 2013 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 100 | 3 | 3 (2) | 3 (2) | 1 |
RfD (mg/kg-day) | 0.18 | 0.0037 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.07 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
3 (ADAF2 to <16) | |||||
1 (ADAF16+) | |||||
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137 (<2) |
0.047 (2 to <16) | |||||
0.039 (16+) | |||||
Endpoints | develop- mental, hepatic (liver) system |
hepatic (liver) system | hepatic (liver) system | hepatic (liver) system | cancer |
CAS number: 67-66-3 | |
Year Adopted: 2018 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 20 | 20 (2) | 20 (2) | NA |
RfD (mg/kg-day) | -- | 0.022 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | developmental, hepatic (liver) system, immune system | developmental, hepatic (liver) system, immune system | developmental, hepatic (liver) system, immune system | -- |
CAS number: 210880-92-5, 205510-53-8 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 200 | 200 (2) | 200 (2) | NA |
RfD (mg/kg-day) | -- | 0.093 | (2) | (2) | -- |
RSC | -- | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental | developmental | -- |
CAS number: 21725-46-2 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 3 | 3 | 3 | 1 | NA |
RfD (mg/kg-day) | 0.0015 | 0.0015 | 0.0012 | 0.00022 | -- |
RSC | 0.5 | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.285 | 0.285 | 0.070 | 0.044 | -- |
Endpoints | developmental, female reproductive system | developmental, female reproductive system | developmental, female reproductive system, hepatic (liver) system, renal (kidney) system | None | -- |
CAS number: 84-74-2 | |
Year Adopted: 2015 | |
Volatility: Low |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 20 | 20 | 20 (2) | 20 (2) | NA |
RfD (mg/kg-day) | 0.023 | 0.023 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | developmental (E) | developmental (E) | developmental (E) | developmental (E) | -- |
CAS number: 75-71-8 | |
Year Adopted: 2011 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | ND | 700 | NA |
RfD (mg/kg-day) | -- | -- | -- | 0.15 | -- |
RSC | -- | -- | -- | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | -- | 0.043 | -- |
Endpoints | -- | -- | -- | None | -- |
CAS number: 107-06-2 | |
Year Adopted: 2013 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 200 | 200 (2) | 60 | 1 |
RfD (mg/kg-day) | -- | 0.23 | (2) | 0.012 | -- |
RSC | -- | 0.2 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.091 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
3 (ADAF2 to <16) | |||||
1 (ADAF16+) | |||||
Intake Rate (L/kg-day) | -- | 0.289 | (2) | 0.043 | 0.137 (<2) |
0.047 (2 to <16) | |||||
0.039 (16+) | |||||
Endpoints | -- | hepatic (liver) system | hepatic (liver) system | renal (kidney) system, hepatic (liver) system | cancer |
CAS number: 156-60-5 | |
Year Adopted: 2013 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 200 | 40 | NA |
RfD (mg/kg-day) | -- | -- | 0.091 | 0.0091 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.077 | 0.043 | -- |
Endpoints | -- | -- | immune system | immune system | -- |
CAS number: 75-35-4 | |
Year Adopted: 2011 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 200 | 200 | NA |
RfD (mg/kg-day) | -- | -- | 0.090 | 0.046 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.077 | 0.043 | -- |
Endpoints | -- | -- | hepatic (liver) system | hepatic (liver) system | -- |
CAS number: 156-59-2 | |
Year Adopted: 2018 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 20 | 10 | 6 | NA |
RfD (mg/kg-day) | -- | 0.033 | 0.0043 | 0.0013 | -- |
RSC | -- | 0.2 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | 0.044 | -- |
Endpoints | -- | hepatic (liver) system | renal (kidney) system | renal (kidney) system | -- |
CAS number: 75-09-2 | |
Year Adopted: 2009 | |
Volatility: High | |
MCL-based HRL: 5 µg/L |
CAS number: 94-75-7 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 30 | 30 (2) | 30 (2) | NA |
RfD (mg/kg-day) | -- | 0.048 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | adrenal, developmental, thyroid (E) | adrenal, developmental, thyroid (E) | adrenal, developmental, thyroid (E) | -- |
CAS number: 60-57-1 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 0.2 | 0.2 (2) | 0.2 | 0.006 |
RfD (mg/kg-day) | -- | 0.00011 | (2) | 0.000043 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 16 |
AFlifetime | -- | -- | -- | -- | 2.5 |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | 0.044 | 0.044 |
Endpoints | -- | developmental, immune system, nervous system | developmental, immune system, nervous system | developmental, hepatic (liver) system, immune system, nervous system | cancer |
CAS number: 117-81-7 | |
Year Adopted: 2015 | |
Volatility: Nonvolatile | |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 20 | 20 | 20 (2) | 20 (2) | 7 |
RfD (mg/kg-day) | 0.029 | 0.029 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.014 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
Endpoints | develop- mental (E), male reproductive system (E) |
develop- mental (E), male reproductive system (E) |
develop- mental (E), male reproductive system (E) |
develop- mental (E), male reproductive system (E) |
cancer |
CAS number: 134-62-3 | |
Year Adopted: 2013 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 200 | 200 (2) | 200 (2) | NA |
RfD (mg/kg-day) | -- | 0.23 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
Endpoints | -- | developmental, nervous system | developmental, nervous system | developmental, nervous system | -- |
CAS numbers: 87674-68-8 and 163515-14-8 | |
Year Adopted: 2015 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 600 | 600 (2) | 300 | NA |
RfD (mg/kg-day) | -- | 0.34 | (2) | 0.060 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | 0.043 | -- |
Endpoints | -- | developmental, female reproductive system, hepatic (liver) system, nervous system | developmental, female reproductive system, hepatic (liver) system, nervous system | hepatic (liver) system | -- |
CAS number: 88-85-7 | |
Year Adopted: 2018 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 8 | 8 (2) | 8 (2) | NA |
RfD (mg/kg-day) | -- | 0.0048 | (2) | (2) | -- |
RSC | -- | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental | developmental | -- |
CAS number: 123-91-1 | |
Year Adopted: 2013 | |
Volatility: Low |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 300 | 100 | 1 |
RfD (mg/kg-day) | -- | -- | 0.12 | 0.025 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.1 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
3 (ADAF2 to <16) | |||||
1 (ADAF16+) | |||||
Intake Rate | -- | -- | 0.077 | 0.043 | 0.137 (<2) |
(L/kg-day) | 0.047 (2 to <16) | ||||
0.039 (16+) | |||||
Endpoints | -- | -- | hepatic (liver) system, renal (kidney) system, respiratory system | hepatic (liver) system, renal (kidney) system, respiratory system | cancer |
CAS number: 100-41-4 | |
Year Adopted: 2011 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 50 | 50 (2) | 50 (2) | NA |
RfD (mg/kg-day) | -- | 0.075 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
Endpoints | -- | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
CAS number: 759-94-4 | |
Year Adopted: 2018 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 300 | 300 | 90 | 40 | NA |
RfD (mg/kg-day) | 0.16 | 0.16 | 0.033 | 0.0083 | -- |
RSC | 0.5 | 0.5 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.285 | 0.285 | 0.070 | 0.044 | -- |
Endpoints | nervous system | developmental, female reproductive system, nervous system | cardiovascular system | cardiovascular system | -- |
CAS number: 107-21-1 | |
Year Adopted: 2011 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 4,000 | 4,000 | 2,000 | 2,000 | NA |
RfD (mg/kg-day) | 0.76 | 0.76 | 0.72 | 0.50 | -- |
RSC | 0.2 | 0.2 | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.043 | 0.043 | 0.077 | 0.043 | -- |
Endpoints | developmental | developmental | renal (kidney) system, developmental | renal (kidney) system, developmental | -- |
CAS number: 206-44-0 | |
Year Adopted: 2018 | |
Volatility: Low |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 200 | 70 | NA |
RfD (mg/kg-day) | -- | -- | 0.053 | 0.016 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
Endpoints | -- | -- | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
CAS number: 51218-45-2; 87392-12-9 | |
Year Adopted: 2011 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 400 | 400 | 300 | 300 (3) | NA |
RfD (mg/kg-day) | 0.24 | 0.24 | 0.097 | (3) | -- |
RSC | 0.5 | 0.5 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | 0.077 | (3) | -- |
Endpoints | developmental | developmental | none | none | -- |
CAS number: 171118-09-5 | |
Year Adopted: 2011 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 4,000 | 800 | NA |
RfD (mg/kg-day) | -- | -- | 1.7 | 0.17 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.077 | 0.043 | -- |
Endpoints | -- | -- | hepatic (liver) system | hepatic (liver) system | -- |
CAS number: 152019-73-3 | |
Year Adopted: 2011 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 3,000 | 3,000 (2) | 800 | NA |
RfD (mg/kg-day) | -- | 1.7 | (2) | 0.17 | -- |
RSC | -- | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | 0.043 | -- |
Endpoints | -- | none | none | none | -- |
CAS number: 21087-64-9 | |
Year Adopted: 2013 | |
Volatility: Low |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 30 | 10 | 10 (2) | 10 (2) | NA |
RfD (mg/kg-day) | 0.016 | 0.006 | (2) | (2) | -- |
RSC | 0.5 | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | developmental, nervous system | thyroid (E) | thyroid (E) | thyroid (E) | -- |
CAS number: 91-20-3 | |
Year Adopted: 2013 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 70 | 70 | 70 (2) | 70 | NA |
RfD (mg/kg-day) | 0.038 | 0.038 | (2) | 0.016 | -- |
RSC | 0.5 | 0.5 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | 0.043 | -- |
Endpoints | nervous system | nervous system | nervous system | nervous system, spleen | -- |
CAS number: 14797-55-8 | |
Year Adopted: 2009 | |
Volatility: Nonvolatile | |
MCL-based HRL: 10,000 µg/L |
CAS number: 87-86-5 | |
Year Adopted: 2015 | |
Volatility: Low | |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 7 | 7 | 7 (2) | 7 (2) | 0.3 |
RfD (mg/kg-day) | 0.0040 | 0.0040 | (2) | (2) | -- |
RSC | 0.5 | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.4 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
Endpoints | develop- mental, thyroid (E) |
develop- mental (E), thyroid (E) |
develop- mental (E), hepatic (liver) system, immune system, male reproductive system, thyroid (E) |
develop- mental (E), hepatic (liver) system, immune system, male reproductive system, thyroid (E) |
cancer |
CAS number: 375-73-5 | |
Year Adopted: 2011 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 9 | 7 | NA |
RfD (mg/kg-day) | -- | -- | 0.0042 | 0.0014 | -- |
RSC | -- | -- | 0.5 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.245 | 0.043 | -- |
Endpoints | -- | -- | hepatic (liver) system, hematological (blood) system, renal (kidney) system | hepatic (liver) system, hematological (blood) system, renal (kidney) system | -- |
CAS number: 45048-62-2; 375-22-4 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 7 | 7 (2) | 7 (2) | NA |
RfD (mg/kg-day) | -- | 0.0038 | (2) | (2) | -- |
RSC | -- | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | hepatic (liver) system, thyroid (E) | -- |
CAS number: 45298-90-6; 1763-23-1; 29081-56-9; 2795-39-3; 70225-14-8; and 29457-72-5 | |
Year Adopted: 2009 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | ND | 0.3 | NA |
RfD (mg/kg-day) | -- | -- | -- | 0.00008 | -- |
RSC | -- | -- | -- | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | -- | 0.049 | -- |
Endpoints | -- | -- | -- | developmental, hepatic (liver) system, thyroid (E) |
-- |
CAS number: 45285-51-6; 335-67-1; 335-66-0; 3825-26-1; 2395-00-8; 335-93-3; and 335-95-5 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 0.035 | 0.035 | 0.035 | NA |
RfD (mg/kg-day) | -- | 0.000018 | 0.000018 | 0.000018 | -- |
RSC | -- | 0.5 | 0.5 | 0.5 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | * | * | * | -- |
Endpoints | -- | developmental, hepatic (liver) system, immune system, renal (kidney) system | developmental, hepatic (liver) system, immune system, renal (kidney) system | developmental, hepatic (liver) system, immune system, renal (kidney) system | -- |
* 95th percentile water intake rates (Tables 3-1 and 3-3), or upper percentile breast milk intake rates (Table 15-1), Environmental Protection Agency (EPA) Exposure Factors Handbook, 2011.
CAS number: 129-00-0 | |
Year Adopted: 2018 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 90 | 50 | NA |
RfD (mg/kg-day) | -- | -- | 0.033 | 0.010 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
Endpoints | -- | -- | renal (kidney) system | renal (kidney) system | -- |
CAS number: 122-34-9 | |
Year Adopted: 2009 | |
Volatility: Nonvolatile | |
MCL-based HRL: 4 µg/L |
CAS number: 57-68-1 (1981-58-4) | |
Year Adopted: 2015 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 100 (2) | 100 (2) | NA |
RfD (mg/kg-day) | -- | 0.040 | (2) | (2) | -- |
RSC | -- | 0.8 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
Endpoints | -- | thyroid | thyroid | thyroid | -- |
CAS number: 127-18-4 | |
Year Adopted: 2009 | |
Volatility: High | |
MCL-based HRL: 5 µg/L |
CAS number: 109-99-9 | |
Year Adopted: 2018 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 600 | 600 (2) | 600 (2) | NA |
RfD (mg/kg-day) | -- | 0.82 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | (2) | (2) | -- |
Endpoints | -- | developmental | developmental | developmental | -- |
CAS number: 153719-23-4 | |
Year Adopted: 2018 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 400 | 200 | 200 (3) | NA |
RfD (mg/kg-day) | -- | 0.25 | 0.057 | (3) | -- |
RSC | -- | 0.5 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.285 | 0.070 | (3) | -- |
Endpoints | -- | developmental, female reproductive system, hepatic (liver) system | male reproductive system | male reproductive system | -- |
CAS number: 108-88-3 | |
Year Adopted: 2011 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 200 | 200 (2) | 200 (2) | NA |
RfD (mg/kg-day) | -- | 0.22 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
Endpoints | -- | immune system, nervous system | immune system, nervous system | immune system, nervous system | -- |
CAS number: 120-82-1 | |
Year Adopted: 2013 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 100 (2) | 100 | 4 |
RfD (mg/kg-day) | -- | 0.17 | (2) | 0.021 | -- |
RSC | -- | 0.2 | (2) | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.029 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
3 (ADAF2 to <16) | |||||
1 (ADAF16+) | |||||
Intake Rate | -- | 0.289 | (2) | 0.043 | 0.137 (<2) |
(L/kg-day) | 0.047 (2 to <16) | ||||
0.039 (16+) | |||||
Endpoints | -- | hepatic (liver) system, adrenal (E), hemato- logical (blood) system |
hepatic (liver) system, adrenal (E), hemato- logical (blood) system |
hepatic (liver) system, adrenal (E), renal (kidney) system | cancer |
CAS number: 71-55-6 | |
Year Adopted: 2018 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 9,000 | 5,000 | NA |
RfD (mg/kg-day) | -- | -- | 3.0 | 1.0 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | -- |
Endpoints | -- | -- | hepatic (liver) system, male reproductive system | hepatic (liver) system, male reproductive system | -- |
CAS number: 79-01-6 | |
Year Adopted: 2015 | |
Volatility: High | |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 0.4 | 0.4 | 0.4 (3) | 2 |
RfD (mg/kg-day) | -- | 0.00052 | 0.00017 | (3) | -- |
RSC | -- | 0.2 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.05 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) 3 (ADAF2 to <16) 1 (ADAF16+) |
Intake Rate (L/kg-day) | -- | 0.289 | 0.077 | (3) | 0.137(<2) 0.047(2 to <16) 0.039(16+) |
Endpoints | -- | develop- mental, immune system |
develop- mental, immune system |
develop- mental, immune system |
cancer |
CAS number: 93-72-1 | |
Year Adopted: 2009 | |
Volatility: Nonvolatile | |
MCL-based HRL: 50 µg/L |
CAS number: 96-18-4 | |
Year Adopted: 2013 | |
Volatility: Moderate |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 7 | 7 | 7 (2) | 7 (2) | 0.003 |
RfD (mg/kg-day) | 0.0042 | 0.0042 | (2) | (2) | -- |
RSC | 0.5 | 0.5 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 30 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
3 (ADAF2 to <16) | |||||
1 (ADAF16+) | |||||
Intake Rate | 0.289 | 0.289 | (2) | (2) | 0.137 (<2) |
(L/kg-day) | 0.047 (2 to <16) | ||||
0.039 (16+) | |||||
Endpoints | develop- mental |
develop- mental |
develop- mental |
develop- mental |
cancer |
CAS number: 108-67-8 | |
Year Adopted: 2009 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 100 | 100 (2) | 100 (2) | NA |
RfD (mg/kg-day) | ND | 0.14 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
Endpoints | -- | hepatic (liver) system | hepatic (liver) system, renal (kidney) system | hepatic (liver) system, renal (kidney) system | -- |
CAS number: 115-96-8 | |
Year Adopted: 2013 | |
Volatility: Low |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 300 | 200 | 200 (3) | 5 |
RfD (mg/kg-day) | -- | 0.15 | 0.068 | (3) | -- |
RSC | -- | 0.5 | 0.2 | (3) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 0.02 |
ADAF or AFlifetime | -- | -- | -- | -- | 10 (ADAF<2) |
3 (ADAF2 to <16) | |||||
1 (ADAF16+) | |||||
Intake Rate | -- | 0.289 | 0.077 | (3) | 0.137 (<2) |
(L/kg-day) | 0.047 (2 to <16) | ||||
0.039 (16+) | |||||
Endpoints | -- | renal (kidney) system, nervous system, develop- mental |
renal (kidney) system | renal (kidney) system | cancer |
CAS number: 75-01-4 | |
Year Adopted: 2018 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | ND | 90 | 10 | 0.2 |
RfD (mg/kg-day) | -- | -- | 0.033 | 0.0030 | -- |
RSC | -- | -- | 0.2 | 0.2 | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | 1.4 |
AFlifetime | -- | -- | -- | -- | 1 |
Intake Rate (L/kg-day) | -- | -- | 0.070 | 0.044 | 0.044 |
Endpoints | -- | -- | hepatic (liver) system | hepatic (liver) system | cancer |
CAS number: 1330-20-7 | |
Year Adopted: 2011 | |
Volatility: High |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | 800 | 300 | 300 (2) | 300 (2) | NA |
RfD (mg/kg-day) | 1.2 | 0.5 | (2) | (2) | -- |
RSC | 0.2 | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | 0.289 | 0.289 | (2) | (2) | -- |
Endpoints | nervous system | nervous system | renal (kidney) system, nervous system | renal (kidney) system, nervous system | -- |
33 SR 1792; 35 SR 1395; 38 SR 397; 40 SR 689; 43 SR 262
September 12, 2018
Notwithstanding the purpose and scope of health risk limits described in part 4717.7810, and as authorized by Minnesota Statutes, section 144.12, subdivision 1, clause (5), the following values are adopted as health risk limits for triclosan.
CAS number: 3380-34-5 | |
Year Adopted: 2015 | |
Volatility: Nonvolatile |
Acute | Short-term | Subchronic | Chronic | Cancer | |
HRL (µg/L) | ND | 50 | 50 (2) | 50 (2) | NA |
RfD (mg/kg-day) | -- | 0.067 | (2) | (2) | -- |
RSC | -- | 0.2 | (2) | (2) | -- |
SF (per mg/kg-day) | -- | -- | -- | -- | -- |
ADAF or AFlifetime | -- | -- | -- | -- | -- |
Intake Rate (L/kg-day) | -- | 0.289 | (2) | (2) | -- |
Endpoints | -- | developmental, female reproductive system (E), hepatic (liver) system, thyroid (E) | developmental, female reproductive system (E), hepatic (liver) system, thyroid (E) | developmental, female reproductive system (E), hepatic (liver) system, thyroid (E) | -- |
40 SR 689
January 4, 2016
Risk from multiple chemicals detected in groundwater must be evaluated as specified in part 4717.7880 for effects other than cancer and in part 4717.7890 for cancer. If a chemical causes both cancer and effects other than cancer, the risk contributed by that chemical must be included in both evaluations. When the multiple chemical health risk index is greater than one, the multiple chemical health risk limit has been exceeded.
MS s 103H.201
33 SR 1792
May 11, 2009
To evaluate the risk of effects other than cancer from multiple chemicals detected in groundwater, a health risk index for each health endpoint must be calculated for each duration period using the procedure specified in this part.
Chemicals must be grouped according to health endpoints, other than cancer, specified in part 4717.7860, and according to duration except that:
Using the following equation, a noncancer health risk index must be determined for each group of two or more chemicals that have a common health endpoint and common duration period.
Noncancer health risk indexduration=C1/nHRL1duration+C2/nHRL2duration+...+CN/nHRLNduration |
Where:
CN represents the concentration expressed as µg/L of the first through Nth chemical. In the case of a chemical that has been detected but cannot be quantified, CN is determined by standard statistical procedures.
MS s 103H.201
33 SR 1792
May 11, 2009
To evaluate the risk of cancer from multiple chemicals detected in groundwater, a cancer health risk index must be calculated using the procedure specified in this part.
To evaluate the risk of cancer from multiple chemicals detected in groundwater, a cancer index must be calculated using the following equation:
Cancer health risk index=C1/cHRL1+C2/cHRL2+...+CN/cHRLN |
Where:
CN represents the concentration expressed as µg/L of the first through Nth chemical. In the case of a chemical that is detected but cannot be quantified, CN is determined by acceptable statistical procedures.
MS s 103H.201
33 SR 1792
May 11, 2009
When testing indicates that chemical breakdown products (degradates) are present in groundwater, it is necessary to consider those breakdown products in a risk assessment. When no health risk limit or other health-based water value exists for a chemical breakdown product, due to absence or paucity of toxicity information on the chemical breakdown product, the health risk limit specified for the parent chemical in part 4717.7860 is the health risk limit for the chemical breakdown product. When a parent and one or more of its breakdown products are present, or when multiple breakdown products are present even in the absence of the parent, it is necessary to conduct a risk assessment for multiple chemicals, according to the procedures in parts 4717.7880 and 4717.7890.
MS s 103H.201
33 SR 1792
May 11, 2009
The purpose of parts 4717.8000 to 4717.8600 is to establish health risk values (HRVs) and multimedia health risk values (MHRVs) for chemicals or defined mixtures of chemicals emitted to the ambient air.
The HRVs and MHRVs established in parts 4717.8000 to 4717.8600 are intended for use by public agencies or private entities in Minnesota as one set of criteria in evaluating risks to human health by chemical emissions to the ambient air. The chemicals and defined mixtures of chemicals included in parts 4717.8000 to 4717.8600 do not include every toxic chemical emitted to air.
The HRVs and MHRVs were not developed for evaluation of workplace exposures. The Occupational Safety and Health Administration, United States Department of Labor, is responsible for regulating workplace exposures.
MS s 144.12
26 SR 1229
May 11, 2009
For the purposes of parts 4717.8000 to 4717.8600, the terms in this part have the meanings given them.
"Acute health risk value" or "acute HRV" means the concentration of a chemical or defined mixture of chemicals in ambient air, at or below which the chemical or defined mixture of chemicals is unlikely to cause an adverse health effect to the general public when exposure occurs over a prescribed time. For implementation purposes, acute HRVs are compared to one-hour averaged concentrations of chemicals or defined mixtures of chemicals in air. An acute HRV is expressed in units of micrograms of the chemical or defined mixture of chemicals per cubic meter of air (µg/m3).
"Additional lifetime risk" means the probability that daily exposure to a carcinogen over a lifetime may induce cancer. The Minnesota Department of Health uses an additional lifetime risk of 1E-5 (1 in 100,000) to set carcinogen exposure guidelines.
"Benchmark concentration" or "BMC" means the statistical lower limit on the concentration of the chemical or defined mixture of chemicals that produces a predetermined change in response rate of an adverse effect (called a benchmark response or BMR) compared to background. The change in response rate over background of the BMR is usually in the range of five to ten percent. The benchmark concentration may be used instead of the NOAEL for noncancer endpoints and is expressed in units of milligrams of chemical or defined mixture of chemicals per cubic meter of air (mg/m3).
"Benchmark dose" or "BMD" means the the statistical lower limit on the dose of the chemical or defined mixture of chemicals that produces a predetermined change in response rate of an adverse effect (called a benchmark response or BMR) compared to background. The change in response rate over background of the BMR is usually in the range of five to ten percent. The benchmark dose may be used instead of the NOAEL for noncancer endpoints and is expressed in units of milligrams of chemical or defined mixture of chemicals per kilogram of body weight per day (mg/kg-day).
"Carcinogen" means a chemical or defined mixture of chemicals:
listed as a human carcinogen or a probable human carcinogen according to "EPA Classification System for Categorizing Weight of Evidence for Carcinogenicity from Human and Animal Studies," The Risk Assessment Guidelines of 1986, United States Environmental Protection Agency, Office of Health and Environmental Assessment (August 1987). The classification system is incorporated by reference, is available through the Minitex interlibrary loan system, and is not subject to frequent change;
listed as "carcinogenic to humans" or "likely to be carcinogenic to humans" according to Proposed Guidelines for Carcinogen Risk Assessment, United States Environmental Protection Agency, Office of Research and Development (July 1999). The guidelines are incorporated by reference, are available through the Minitex interlibrary loan system, and are not subject to frequent change; or
listed as a substance known to be a human carcinogen or reasonably anticipated to be a human carcinogen in the Report on Carcinogens, United States Department of Health and Human Services, Public Health Service, National Toxicology Program. The report is incorporated by reference and is subject to frequent change. The report is available on the Internet at http://ntp-server.niehs.nih.gov/newhomeroc/aboutroc.html.
"Chemical abstracts service registry number" or "CAS RN" means the number assigned to a chemical by the Chemical Abstracts Service, a division of the American Chemical Society, 2540 Olentangy River Road, Box 3012, Columbus, Ohio 43210. The chemical abstracts service registry numbers are published in Chemical Abstracts Service Registry Handbook - Number Section, American Chemical Society (1965). The handbook is incorporated by reference, is available through the Minitex interlibrary loan system, and is subject to annual change.
"Chronic health risk value" or "chronic HRV" means the concentration of a chemical or defined mixture of chemicals in ambient air, at or below which the chemical or defined mixture of chemicals is unlikely to cause an adverse health effect to the general public when exposure occurs daily throughout a person's lifetime. For implementation purposes, chronic HRVs are compared to an annual average concentration of a chemical or defined mixture of chemicals in air. A chronic HRV is expressed in units of micrograms of the chemical or defined mixture of chemicals per cubic meter of air (µg/m3).
"Cumulative health risk value" or "cumulative HRV" is a HRV calculated by summing the hazard quotients of chemicals sharing a common endpoint. A hazard quotient for a particular chemical is calculated by dividing the measured or modeled ambient air concentrations for a chemical by the HRV for that chemical. The equation used to calculate a cumulative HRV or hazard index for noncarcinogenic effects of chemicals is found in part 4717.8600. The equation used to calculate a cumulative HRV or cancer index for carcinogens is found in part 4717.8550.
"Cumulative multimedia health risk value" or "cumulative MHRV" is a MHRV calculated by summing the hazard quotients of chemicals sharing a common endpoint. A hazard quotient for a particular chemical is calculated by dividing the measured or modeled ambient air concentrations for a chemical by the MHRV for that chemical. The equation used to calculate a cumulative MHRV or hazard index for noncarcinogenic effects of chemicals is found in part 4717.8600. The equation used to calculate a cumulative MHRV or cancer index for carcinogens is found in part 4717.8550.
"Defined mixture of chemicals" means a mixture of chemical compounds where the toxicity of that mixture of chemical compounds is quantified as a group, rather than individually, in an analytical procedure. Defined mixtures of chemicals include, but are not limited to, coke oven emissions, diesel particulate, and nickel refinery dust.
"Endpoint of concern" or "endpoint" means an observable and measurable adverse biological event used as a scientifically defensible index of an effect of a low dose chemical exposure. The designation of an endpoint of concern does not exclude other possible observable and measurable biological events.
"Extrarespiratory effect" means a toxic effect produced at a site other than the respiratory system following inhalation of a chemical.
"Extrarespiratory regional dose deposition" or "RDDER" is the estimated amount of inhaled chemical or defined mixture of chemicals that is transported to nonrespiratory tract tissues after absorption of the chemical has occurred. The default normalizing factor for extrarespiratory effects is body weight. Until clearance and distribution parameters can be incorporated, it is assumed that 100 percent of a deposited dose to the entire respiratory system is available for uptake by the systemic circulation.
"Extrarespiratory regional dose deposition ratio" or "RDDRER" means the ratio of the extrarespiratory regional dose deposition calculated for an experimental animal to the calculated extrarespiratory regional dose deposition in a human.
"(Hb/g)A" means the blood to gas (air) partition coefficient of a chemical in an experimental animal.
"(Hb/g)H" means the blood to gas (air) partition coefficient of a chemical in a human.
"Health effects assessment summary tables" or "HEAST" means the health effects assessment summary tables prepared by the United States Environmental Protection Agency, Office of Research and Development (1991). The tables are incorporated by reference, are available through the Minitex interlibrary loan system, and are subject to quarter-annual changes.
"Health risk value" or "HRV" means the concentration of a chemical or defined mixture of chemicals in ambient air, at or below which the chemical or defined mixture of chemicals is unlikely to cause an adverse health effect to the general public. The HRV is expressed in units of micrograms of the chemical or defined mixture of chemicals per cubic meter of air (µg/m3).
"Human equivalent concentration" or "HEC" means the concentration of inhalation exposure for humans of an agent that is believed to induce the same magnitude of a toxic effect as associated with the experimental animal species exposure concentration. HEC derivation may incorporate toxicokinetic information on the particular agent, if available, or use a default procedure, such as assuming that daily oral doses experienced for a lifetime are proportional to body weight raised to the 0.75 power.
"Integrated risk information system" or "IRIS" means the United States Environmental Protection Agency's electronic database for toxicologic information on chemicals. The IRIS is updated monthly and is available on the Internet at the website of the United States Environmental Protection Agency (www.epa.gov/iris/). The database is incorporated by reference and is subject to frequent change.
"Lowest observed adverse effect level" or "LOAEL" means the lowest exposure dose or concentration of a chemical or defined mixture of chemicals at which adverse effects have been observed in test animals or human test subjects and where the adverse effects are statistically different from background or a control group. The LOAEL is expressed in units of either milligrams of a chemical or defined mixture of chemicals per cubic meter of air (mg/m3) for inhalation exposures or units of milligrams of a chemical or defined mixture of chemicals per kilogram of body weight per day (mg/kg-day) for multimedia exposures.
"Lowest observed adverse effect level adjusted" or "LOAEL[ADJ]" means the lowest observed adverse effect level for a chemical or defined mixture of chemicals adjusted to a specific period of time. For the chronic HRVs, the concentration in the scientific study is adjusted to a 24-hour per day, seven-day per week exposure period. For acute HRVs, the adjustment may include either a time adjustment to a one-hour exposure period or an adjustment for concentration as indicated in part 4717.8500, subparts 3, 4, and 5.
"Modifying factor" means a factor used in the derivation of a reference dose or reference concentration. The magnitude of the modifying factor reflects the scientific uncertainties of the study and database not explicitly treated with standard uncertainty factors (e.g., the completeness of the overall database). A modifying factor is greater than zero and less than or equal to ten, and the default value for the modifying factor is one.
"Multimedia health risk value" or "MHRV" means the total daily dose of a chemical or defined mixture of chemicals that results from an emission to ambient air, at or below which is unlikely to cause an adverse health effect to the general public over a lifetime exposure. Total daily dose is the sum of the exposure doses calculated from applicable inhalation or noninhalation exposure pathways. The MHRV is expressed in units of micrograms of the chemical or defined mixture of chemicals per kilogram of body weight per day (µg/kg-day).
"No observed adverse effect level" or "NOAEL" means the highest exposure level at which there are no statistically or biologically significant increases in the frequency or severity of adverse effect between the exposed population and its appropriate control. Some effects may be produced at this level, but they are not considered adverse or precursors to adverse effects. The NOAEL is expressed in units of milligrams of chemical or defined mixture of chemicals per cubic meter of air (mg/m3) or milligrams of chemical or defined mixture of chemicals per kilogram of body weight per day (mg/kg-day).
"No observed adverse effect level adjusted" or "NOAEL[ADJ]" means the no observed adverse effect level for a chemical or defined mixture of chemicals adjusted to a specific period of time. For the chronic HRVs, the concentration is adjusted to a 24-hour per day, seven-day per week exposure period. For acute HRVs, the adjustment may include either a time adjustment to the scientific study data to a one-hour exposure period or an adjustment for concentration as indicated in part 4717.8500, subparts 3 and 4.
"Potency slope" or "slope factor" means an upper bound, approximating a 95 percent confidence limit, on the increased cancer risk from a lifetime exposure to a chemical or defined mixture of chemicals. This estimate, usually expressed in units of proportion (of a population) affected per mg/kg/day, is generally reserved for use in the low-dose region of the dose-response relationship, that is, for exposures corresponding to risks less than one in 100. This number is derived from a mathematical extrapolation model that uses toxicologic data specific to each carcinogen. The potency slope for a carcinogen by ingestion is expressed in units of the inverse of milligrams of the chemical or defined mixture of chemicals per kilogram of body weight per day (mg/kg-day)-1.
"Reference concentration" or "RfC" means an estimate, with uncertainty spanning perhaps an order of magnitude, of a continuous inhalation exposure to the human population, including sensitive subgroups, that is likely to be without an appreciable risk or deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark concentration, with uncertainty factors generally applied to reflect limitations on the scientific data available. The RfC is expressed in units of milligrams of the chemical or defined mixture of chemicals per cubic meter of air (mg/m3).
"Reference dose" or "RfD" means an estimate, with uncertainty spanning perhaps an order of magnitude, of a daily oral exposure to the human population, including sensitive subgroups, that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark dose, with uncertainty factors generally applied to reflect limitations of the scientific data available. The RfD is expressed in units of milligrams of the chemical or defined mixture of chemicals per kilogram of body weight per day (mg/kg-day).
"Reference exposure level" or "REL" means the concentration level of a chemical or defined mixture of chemicals at or below which no adverse health effects are anticipated for a specified exposure duration. Reference exposure levels have been derived by the California Environmental Protection Agency, the Office of Environmental Health Hazard Assessment, under the Air Toxics "Hot Spots" Information and Assessment Act of 1987. The exposure levels are available on the Internet at the website of the Office of Environmental Health Hazard Assessment (www.oehha.org/air/acute_rels/acuterel.html).
"Regional deposited dose" or "RDD" means the deposited dose of particles calculated for a respiratory tract region of interest as related to an observed toxicity. For respiratory effects of particles, the deposited dose is adjusted for ventilatory volumes and the surface area of the respiratory region affected and is expressed as milligrams per minute per square centimeter (mg/min-sq. cm). For extrarespiratory effects of particles, the deposited dose in the total respiratory system is adjusted for ventilatory volumes and body weight and is expressed as milligrams per minute per kilogram (mg/min-kg).
"Regional deposited dose ratio" or "RDDR" means the ratio of the regional deposited dose calculated for a given exposure in the animal species of interest (RDDA) to the regional deposited dose of the same exposure in a human (RDDH). This ratio is used to adjust the exposure effect level for interspecies dosimetric differences to derive a human equivalent concentration (HEC) for particles.
"Regional gas dose" or "RGD" means the gas dose calculated for the respiratory system region of interest as related to the observed effect for respiratory effects. The deposited dose is adjusted for ventilatory volumes and the surface area of the respiratory region affected. RGD is calculated per minute expressed as milligrams per minute per square centimeter (mg/min-sq. cm).
"Regional gas dose ratio" or "RGDR" means the ratio of the regional gas dose calculated for a given exposure in the animal species of interest (RGDA) to the regional gas dose of the same exposure in humans (RGDH). This ratio is used to adjust the exposure effect level for interspecies dosimetric differences to derive a human equivalent concentration (HEC) for gases with respiratory effects.
"Respiratory effect" means a toxic effect produced in the respiratory system. Respiratory effects are divided into the categories of upper respiratory effects and lower respiratory effects. Effects in the upper respiratory system consist of effects primarily in the extrathoracic (ET) region, consisting of the nose, mouth, nasopharynx, oropharynx, laryngopharynx, and larynx, and in the upper tracheobronchial (TB) region consisting of the trachea, bronchi, and bronchioles.
The lower respiratory system effects consist of effects primarily in the pulmonary (PU) region, consisting of the respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli, and effects in the lower tracheobronchial (TB) region, consisting of the trachea and bronchioles to the terminal bronchioles.
"Respiratory system" means the nose, mouth, nasopharynx, oropharynx, larynx, trachea, bronchi, bronchioles, and the alveolar ducts, alveolar sacs, and alveoli of the lung.
"Statistical significance" means the probability that a result is likely to be due to chance alone. By convention, a difference between two groups is usually considered statistically significant if chance could explain it only five percent of the time or less. Study design considerations may influence the a priori choice of a different statistical significance level.
"Subchronic health risk value" or "subchronic HRV" means the concentration of a chemical or defined mixture of chemicals in ambient air at or below which the chemical or defined mixture of chemicals is unlikely to cause an adverse health effect to the general public when exposure occurs on a continuous basis over a less than lifetime exposure. For implementation purposes, subchronic HRVs are compared to a 13-week averaged concentration of a chemical or defined mixture of chemicals in ambient air. A subchronic HRV is expressed in units of micrograms of the chemical or defined mixture of chemicals per cubic meter of air (µg/m3).
"Uncertainty factor" means the numerical factors used to account for the variation in sensitivity among members of the human population; the uncertainty in extrapolating laboratory animal data to humans; the uncertainty in extrapolating from data obtained in a study that involves less than lifetime exposure to lifetime exposure; the uncertainty in using LOAEL data due to the absence of NOAEL data; and the inability of any single study to adequately address all possible adverse outcomes in humans.
"Unit risk" means the upper bound excess cancer risk from a continuous lifetime exposure to a chemical or defined mixture of chemical concentration at one microgram per cubic meter (1 µg/m3) in air.
MS s 144.12
26 SR 1229; 26 SR 1395
September 7, 2018
The heading for each item contains the chemical name and, in parenthesis, the CAS RN. Each item lists the chronic HRV, the equation used to develop the chronic HRV, and the variables necessary for the equation. The equations used to develop the chronic HRV are designated as follows:
"A" means calculating the NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] under part 4717.8300, subpart 3, and applying the general equation under part 4717.8300, subpart 2;
"B" means calculating the NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] under part 4717.8300, subpart 4, and applying the general equation under part 4717.8300, subpart 2;
"C" means calculating the NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] under part 4717.8300, subpart 5, and applying the general equation under part 4717.8300, subpart 2;
"D" means calculating the NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] under part 4717.8300, subpart 6, and applying the general equation under part 4717.8300, subpart 2; and
"E" means applying the equation under part 4717.8400, subpart 2.
The endpoint of concern is listed for use in determining a cancer index under part 4717.8550 or a hazard index under part 4717.8600. The unit risk for carcinogens is expressed as risk per (µg/m3).
TABLE OF CHRONIC HRVs
Acetaldehyde (75-07-0)
Chronic HRV (µg/m3) | 5 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 2.2E-6 |
Acetonitrile (75-05-8)
Chronic HRV (µg/m3) | 60 |
Endpoint of concern | Mortality |
Equation | D |
NOAEL[HEC] (mg/m3) | 6E1 |
Uncertainty factor | 1,000 |
Acrylonitrile (107-13-1)
Chronic HRV (µg/m3) | 0.1 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 6.8E-5 |
Ammonia (7664-41-7)
Chronic HRV (µg/m3) | 80 |
Endpoint of concern | Upper and lower respiratory system |
Equation | C |
NOAEL[HEC] (mg/m3) | 2.3 |
Uncertainty factor | 30 |
Antimony trioxide (1309-64-4)
Chronic HRV (µg/m3) | 0.2 |
Endpoint of concern | Lower respiratory system |
Equation | A |
BMC[HEC] (mg/m3) | 7.4E-2 |
Uncertainty factor | 300 |
Arsenic (7440-38-2)
Chronic HRV (µg/m3) | 0.002 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 4.3E-3 |
Benzene (71-43-2)
Chronic HRV (µg/m3) | 1.3 - 4.5 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 2.2E-6 to 7.8E-6 |
Benzidine (92-87-5)
Chronic HRV (µg/m3) | 0.0002 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 6.7E-2 |
Beryllium (7440-41-7)
Chronic HRV (µg/m3) | 0.004 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 2.4E-3 |
Bis(chloromethyl)ether (542-88-1)
Chronic HRV (µg/m3) | 0.0002 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 6.2E-2 |
Bromomethane (74-83-9)
Chronic HRV (µg/m3) | 5 |
Endpoint of concern | Upper respiratory system |
Equation | C |
LOAEL[HEC] (mg/m3) | 4.8E-1 |
Uncertainty factor | 100 |
1,3-Butadiene (106-99-0)
Chronic HRV (µg/m3) | 0.04 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 2.8E-4 |
Cadmium (7440-43-9)
Chronic HRV (µg/m3) | 0.006 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 1.8E-3 |
Carbon disulfide (75-15-0)
Chronic HRV (µg/m3) | 700 |
Endpoint of concern | Nervous system |
Equation | D |
BMC[HEC] (mg/m3) | 1.97E1 |
Uncertainty factor | 30 |
2-Chloroacetophenone (532-27-4)
Chronic HRV (µg/m3) | 0.03 |
Endpoint of concern | Upper and lower respiratory system |
Equation | C |
LOAEL[HEC] (mg/m3) | 3E-2 |
Uncertainty factor | 1,000 |
Chromium VI (18540-29-9)
Chronic HRV (µg/m3) | 0.0008 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 1.2E-2 |
Coke oven emissions (8007-45-2)
Chronic HRV (µg/m3) | 0.02 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 6.2E-4 |
1,2-Dibromoethane (106-93-4)
Chronic HRV (µg/m3) | 0.05 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 2.2E-4 |
Dichloromethane (75-09-2)
Chronic HRV (µg/m3) | 20 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 4.7E-7 |
1,3-Dichloropropene (542-75-6)
Chronic HRV (µg/m3) | 20 |
Endpoint of concern | Upper respiratory system |
BMC[HEC] (mg/m3) | 7.2E-1 |
Equation | C |
Uncertainty factor | 30 |
Dichlorvos (62-73-7)
Chronic HRV (µg/m3) | 0.5 |
Endpoint of concern | Nervous system |
Equation | D |
NOAEL[HEC] (mg/m3) | 5E-2 |
Uncertainty factor | 100 |
Diesel particulates (*)
Chronic HRV (µg/m3) | 5 |
Endpoint of concern | Lower respiratory system |
Equation | A |
NOAEL[HEC] (mg/m3) | 1.55E-1 |
Uncertainty factor | 30 |
N,N-dimethylformamide (68-12-2)
Chronic HRV (µg/m3) | 30 |
Endpoint of concern | Gastrointestinal system and hepatic system |
Equation | D |
LOAEL[HEC] (mg/m3) | 7.9 |
Uncertainty factor | 300 |
Epichlorohydrin (106-89-8)
Chronic HRV (µg/m3) | 8 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 1.2E-6 |
1,2-Epoxybutane (106-88-7)
Chronic HRV (µg/m3) | 20 |
Endpoint of concern | Upper respiratory system |
Equation | C |
LOAEL[HEC] (mg/m3) | 4.8 |
Uncertainty factor | 300 |
Ethylene glycol monobutyl ether (111-76-2)
Chronic HRV (µg/m3) | 13,000 |
Endpoint of concern | Hematologic system |
Equation | D |
BMC[HEC] (mg/m3) | 3.8E2 |
Uncertainty factor | 30 |
Formaldehyde (50-00-0)
Chronic HRV (µg/m3) | 0.8** |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 1.3E-5 |
1,6-Hexamethylene diisocyanate (822-06-0)
Chronic HRV (µg/m3) | 0.01** |
Endpoint of concern | Upper and lower respiratory system |
Equation | C |
NOAEL[HEC] (mg/m3) | 1E-3 |
Uncertainty factor | 100 |
n-Hexane (110-54-3)
Chronic HRV (µg/m3) | 2,000 |
Endpoint of concern | Nervous system and upper respiratory system |
Equation | D |
LOAEL[HEC] (mg/m3) | 7.3E1 |
Uncertainty factor | 30 |
Hydrazine/Hydrazine sulfate (302-01-2)
Chronic HRV (µg/m3) | 0.002 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 4.9E-3 |
Hydrogen chloride (7647-01-0)
Chronic HRV (µg/m3) | 20 |
Endpoint of concern | Upper respiratory system |
Equation | C |
LOAEL[HEC] (mg/m3) | 6.1 |
Uncertainty factor | 300 |
Hydrogen cyanide (74-90-8)
Chronic HRV (µg/m3) | 3 |
Endpoint of concern | Endocrine system and nervous system |
Equation | D |
LOAEL[HEC] (mg/m3) | 2.5 |
Uncertainty factor | 1,000 |
Manganese (7439-96-5)
Chronic HRV (µg/m3) | 0.2 |
Endpoint of concern | Nervous system |
Equation | B |
BMC[HEC] (mg/m3) | 1.9E-2 |
Uncertainty factor | 100 |
Methyl methacrylate (80-62-6)
Chronic HRV (µg/m3) | 700** |
Endpoint of concern | Upper and lower respiratory system |
Equation | C |
BMC[HEC] (mg/m3) | 7.2 |
Uncertainty factor | 10 |
Methylene diphenyl diisocyanate (MDI) and polymeric MDI (101-68-8 and 9016-87-9)
Chronic HRV (µg/m3) | 0.6** |
Endpoint of concern | Upper and lower respiratory system |
Equation | A |
BMC[HEC] (mg/m3) | 6E-2 |
Uncertainty factor | 100 |
Nickel refinery dust (*)
Chronic HRV (µg/m3) | 0.04 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 2.4E-4 |
Nickel subsulfide (12035-72-2)
Chronic HRV (µg/m3) | 0.02 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 4.8E-4 |
2-Nitropropane (79-46-9)
Chronic HRV (µg/m3) | 20 |
Endpoint of concern | Hepatic system |
Equation | D |
LOAEL[HEC] (mg/m3) | 1.6E1 |
Uncertainty factor | 1,000 |
Propylene oxide (75-56-9)
Chronic HRV (µg/m3) | 3 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 3.7E-6 |
Styrene (100-42-5)
Chronic HRV (µg/m3) | 1000 |
Endpoint of concern | Nervous system |
Equation | D |
NOAEL[HEC] (mg/m3) | 3.4E1 |
Uncertainty factor | 30 |
Toluene (108-88-3)
Chronic HRV (µg/m3) | 400 |
Endpoint of concern | Nervous system and upper respiratory system |
Equation | D |
LOAEL[HEC] (mg/m3) | 1.19E2 |
Uncertainty factor | 300 |
2,4-/2,6-Toluene diisocyanate (26471-62-5)
Chronic HRV (µg/m3) | 0.08** |
Endpoint of concern | Lower respiratory system |
Equation | D |
NOAEL[HEC] (mg/m3) | 2.3E-3 |
Uncertainty factor | 30 |
Vinyl acetate (108-05-4)
Chronic HRV (µg/m3) | 200 |
Endpoint of concern | Upper respiratory system |
Equation | C |
NOAEL[HEC] (mg/m3) | 5 |
Uncertainty factor | 30 |
Vinyl chloride (75-01-4)
Chronic HRV (µg/m3) | 1 |
Endpoint of concern | Cancer |
Equation | E |
Unit risk | 8.8E-6 |
* This HRV is for a chemical mixture which, therefore, does not have a chemical-specific number assigned by the Chemical Abstracts Service.
** This HRV may not provide protection for individuals who have been previously sensitized to this chemical.
MS s 144.12
26 SR 1229; 26 SR 1395
January 5, 2016
The heading for each item contains the chemical name and, in parenthesis, the CAS RN. Each item lists the subchronic HRV, the equation used to develop the subchronic HRV, and the variables necessary for the equation. The equations used to develop the subchronic HRV are designated as follows:
"A" means calculating the NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] under part 4717.8300, subpart 3, and applying the general equation under part 4717.8300, subpart 2;
"B" means calculating the NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] under part 4717.8300, subpart 4, and applying the general equation under part 4717.8300, subpart 2;
"C" means calculating the NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] under part 4717.8300, subpart 5, and applying the general equation under part 4717.8300, subpart 2; and
"D" means calculating the NOAEL[HEC] or LOAEL[HEC] or BMC [HEC] under part 4717.8300, subpart 6, and applying the general equation under part 4717.8300, subpart 2.
The endpoint of concern is listed for use in determining a hazard index under part 4717.8600.
TABLE OF SUBCHRONIC HRVs
Acrolein (107-02-8)
Subchronic HRV (µg/m3) | 0.2 |
Endpoint of concern | Upper respiratory system |
Equation | C |
LOAEL[HEC] (mg/m3) | 2E-2 |
Uncertainty factor | 100 |
Acrylic acid (79-10-7)
Subchronic HRV (µg/m3) | 3 |
Endpoint of concern | Upper respiratory system |
Equation | C |
LOAEL[HEC] (mg/m3) | 3.3E-1 |
Uncertainty factor | 100 |
Allyl chloride (107-05-1)
Subchronic HRV (µg/m3) | 10 |
Endpoint of concern | Nervous system |
Equation | D |
NOAEL[HEC] (mg/m3) | 3.6 |
Uncertainty factor | 300 |
Arsine (7784-42-1)
Subchronic HRV (µg/m3) | 0.1 |
Endpoint of concern | Hematologic system |
Equation | D |
NOAEL[HEC] (mg/m3) | 1.4E-2 |
Uncertainty factor | 100 |
Chlordane (12789-03-6)
Subchronic HRV (µg/m3) | 7 |
Endpoint of concern | Hepatic system |
Equation | B |
NOAEL[HEC] (mg/m3) | 6.5E-1 |
Uncertainty factor | 100 |
Chlorine dioxide (10049-04-4)
Subchronic HRV (µg/m3) | 0.6 |
Endpoint of concern | Lower respiratory system |
Equation | C |
LOAEL[HEC] (mg/m3) | 6.4E-1 |
Uncertainty factor | 1,000 |
Chromic acid mists and dissolved Cr (VI) aerosols (18540-29-9)
Subchronic HRV (µg/m3) | 0.02 |
Endpoint of concern | Upper and lower respiratory system |
Equation | C |
LOAEL[ADJ] (mg/m3) | 7.1E-4 |
Uncertainty factor | 30 |
Cr (VI) particulates (18540-29-9)
Subchronic HRV (µg/m3) | 1 |
Endpoint of concern | Lower respiratory system |
Equation | A |
BMC[HEC] (mg/m3) | 3.5E-2 |
Uncertainty factor | 30 |
Cumene (98-82-8)
Subchronic HRV (µg/m3) | 4,000 |
Endpoint of concern | Renal system and endocrine system |
Equation | D |
NOAEL[HEC] (mg/m3) | 4.35E2 |
Uncertainty factor | 100 |
1,2-Dibromo-3-chloropropane (96-12-8)
Subchronic HRV (µg/m3) | 2 |
Endpoint of concern | Male reproductive system |
Equation | D |
NOAEL[HEC] (mg/m3) | 1.7E-1 |
Uncertainty factor | 100 |
1,4-Dichlorobenzene (106-46-7)
Subchronic HRV (µg/m3) | 800 |
Endpoint of concern | Hepatic system |
Equation | D |
NOAEL[HEC] (mg/m3) | 7.5E1 |
Uncertainty factor | 100 |
1,2-Dichloropropane (78-87-5)
Subchronic HRV (µg/m3) | 10 |
Endpoint of concern | Upper respiratory system |
Equation | C |
LOAEL[HEC] (mg/m3) | 1.3 |
Uncertainty factor | 100 |
Dicyclopentadiene (77-73-6)
Subchronic HRV (µg/m3) | 3 |
Endpoint of concern | Renal system |
Equation | D |
LOAEL[HEC] (mg/m3) | 9.6E-1 |
Uncertainty factor | 300 |
2-Dimethylamino ethanol (101-01-0)
Subchronic HRV (µg/m3) | 70 |
Endpoint of concern | Upper respiratory system |
Equation | C |
NOAEL[HEC] (mg/m3) | 1.96 |
Uncertainty factor | 30 |
Ethylene glycol monomethyl ether (EGME) or 2-methoxyethanol (109-86-4)
Subchronic HRV (µg/m3) | 60 |
Endpoint of concern | Male reproductive and hematologic systems |
Equation | D |
NOAEL[HEC](mg/m3) | 1.7E1 |
Uncertainty factor | 300 |
Hydrogen sulfide (7783-06-4)
Subchronic HRV (µg/m3) | 10 |
Endpoint of concern | Upper respiratory system |
Equation | C |
NOAEL[HEC] (mg/m3) | 1.01 |
Uncertainty factor | 100 |
Phosphine (7803-51-2)
Subchronic HRV (µg/m3) | 3 |
Endpoint of concern | Decreased body weight |
Equation | D |
NOAEL[HEC] (mg/m3) | 2.5E-1 |
Uncertainty factor | 100 |
Propylene glycol monomethyl ether (107-98-2)
Subchronic HRV (µg/m3) | 20,000 |
Endpoint of concern | Nervous system |
Equation | D |
NOAEL[HEC] (mg/m3) | 6.58E2 |
Uncertainty factor | 30 |
Triethylamine (121-44-8)
Subchronic HRV (µg/m3) | 70 |
Endpoint of concern | Upper respiratory system |
Equation | C |
NOAEL[HEC] (mg/m3) | 1.95E1 |
Uncertainty factor | 300 |
MS s 144.12
26 SR 1229; 26 SR 1395
January 4, 2016
The heading for each item contains the chemical name and, in parenthesis, the CAS RN. Each item lists the acute HRV, the equation used to develop the acute HRV, and the variables necessary for the equation. The equations used to develop the acute HRV are designated as follows:
"A" means calculating the NOAEL or LOAEL or BMC[ADJ] under part 4717.8500, subpart 3, and applying the general equation under part 4717.8500, subpart 2;
"B" means calculating the NOAEL[ADJ] or LOAEL[ADJ] or BMC [ADJ] under part 4717.8500, subpart 4, and applying the general equation under part 4717.8500, subpart 2;
"C" means calculating the BMC or BMC[ADJ] under part 4717.8500; and
"D" means applying the equation under part 4717.8500, subpart 5.
The endpoint of concern is listed for use in determining a hazard index under part 4717.8600.
TABLE OF ACUTE HRVs
Ammonia (7664-41-7)
Acute HRV (µg/m3) | 3,200 |
Endpoint of concern | Irritant - eye, respiratory system |
Equation | C |
BMC (mg/m3) | 9.5 |
Uncertainty factor | 3 |
Arsine (7784-42-1)
Acute HRV (µg/m3) | 200 |
Endpoint of concern | Hematologic* |
Equation | A |
NOAEL[ADJ] (mg/m3) | 1.6E1 |
Uncertainty factor | 100 |
Benzene (71-43-2)
Acute HRV (µg/m3) | 1,000 |
Endpoint of concern | Reproductive/developmental |
Equation | D |
NOAEL (mg/m3) | 1.3E2 |
Uncertainty factor | 100 |
Carbon disulfide (75-15-0)
Acute HRV (µg/m3) | 6,000 |
Endpoint of concern | Reproductive/developmental |
Equation | D |
NOAEL (mg/m3) | 6.2E2 |
Uncertainty factor | 100 |
Chlorine (7882-50-5)
Acute HRV (µg/m3) | 290 |
Endpoint of concern | Irritant - respiratory system |
Equation | A |
NOAEL (mg/m3) | 2.9 |
Uncertainty factor | 10 |
Chloroform (67-66-3)
Acute HRV (µg/m3) | 150 |
Endpoint of concern | Reproductive/developmental |
Equation | D |
LOAEL (mg/m3) | 1.5E2 |
Uncertainty factor | 1,000 |
Dichloromethane (75-09-2)
Acute HRV (µg/m3) | 10,000 |
Endpoint of concern | Nervous system |
Equation | A |
NOAEL[ADJ] (mg/m3) | 6.8E2 |
Uncertainty factor | 60 |
1,4-Dioxane (123-91-1)
Acute HRV (µg/m3) | 3,000 |
Endpoint of concern | Irritant - eye and nasal |
Equation | A |
LOAEL[ADJ] (mg/m3) | 1.8E2 |
Uncertainty factor | 60 |
Ethyl benzene (100-41-4)
Acute HRV (µg/m3) | 10,000 |
Endpoint of concern | Reproductive/developmental |
Equation | D |
NOAEL (mg/m3) | 4.3E2 |
Uncertainty factor | 30 |
Ethyl chloride (75-00-3)
Acute HRV (µg/m3) | 100,000 |
Endpoint of concern | Reproductive/developmental |
Equation | D |
NOAEL (mg/m3) | 4E3 |
Uncertainty factor | 30 |
Ethylene glycol monoethyl ether (110-80-5)
Acute HRV (µg/m3) | 400 |
Endpoint of concern | Reproductive/developmental |
Equation | D |
NOAEL (mg/m3) | 3.7E1 |
Uncertainty factor | 100 |
Ethylene glycol monoethyl ether acetate (111-15-9)
Acute HRV (µg/m3) | 100 |
Endpoint of concern | Reproductive/developmental |
Equation | D |
LOAEL (mg/m3) | 1.4E2 |
Uncertainty factor | 1,000 |
Ethylene glycol monomethyl ether (EGME) (109-86-4) or 2-methoxyethanol
Acute HRV (µg/m3) | 90 |
Endpoint of concern | Reproductive/developmental |
Equation | D |
NOAEL (mg/m3) | 9.3 |
Uncertainty factor | 100 |
Formaldehyde (50-00-0)
Acute HRV (µg/m3) | 94 |
Endpoint of concern | Irritant - eye and respiratory system |
Equation | C |
BMC (mg/m3) | 9.4E-1 |
Uncertainty factor | 10 |
Hydrogen chloride (7647-01-1)
Acute HRV (µg/m3) | 2,700 |
Endpoint of concern | Irritant - eye and respiratory system |
Equation | A |
NOAEL (mg/m3) | 2.7 |
Uncertainty factor | 1 |
Hydrogen cyanide (74-90-8)
Acute HRV (µg/m3) | 700 |
Endpoint of concern | Nervous system* |
Equation | A |
NOAEL (mg/m3) | 6.8E1 |
Uncertainty factor | 100 |
Hydrogen fluoride (7664-39-3)
Acute HRV (µg/m3) | 240 |
Endpoint of concern | Irritant - respiratory system |
Equation | A |
NOAEL[ADJ] (mg/m3) | 2.4 |
Uncertainty factor | 10 |
Methanol (67-56-1)
Acute HRV (µg/m3) | 25,000 |
Endpoint of concern | Nervous system |
Equation | A |
NOAEL[ADJ] (mg/m3) | 2.5E2 |
Uncertainty factor | 10 |
Methyl bromide (74-83-9)
Acute HRV (µg/m3) | 2,000 |
Endpoint of concern | Nervous system* |
Equation | A |
LOAEL[ADJ] (mg/m3) | 1.4E2 |
Uncertainty factor | 60 |
Methyl ethyl ketone (78-93-3)
Acute HRV (µg/m3) | 10,000 |
Endpoint of concern | Irritant - eye and respiratory system |
Equation | A |
LOAEL[ADJ] (mg/m3) | 8E2 |
Uncertainty factor | 60 |
Nickel and nickel compounds (**)
Acute HRV (µg/m3) | 11 |
Endpoint of concern | Irritant - respiratory system |
Equation | A |
LOAEL (mg/m3) | 6.7E-2 |
Uncertainty factor | 6 |
Nitric acid (7697-37-2)
Acute HRV (µg/m3) | 130 |
Endpoint of concern | Irritant - respiratory system |
Equation | A |
NOAEL (mg/m3) | 1.29E-1 |
Uncertainty factor | 1 |
Phenol (108-95-2)
Acute HRV (µg/m3) | 5,800 |
Endpoint of concern | Irritant - eye and respiratory system |
Equation | B |
NOAEL[ADJ] (mg/m3) | 5.8E1 |
Uncertainty factor | 10 |
Phosgene (75-44-5)
Acute HRV (µg/m3) | 4 |
Endpoint of concern | Irritant - respiratory system* |
Equation | A |
NOAEL[ADJ] (mg/m3) | 4E-1 |
Uncertainty factor | 100 |
Sodium hydroxide (1310-93-2)
Acute HRV (µg/m3) | 8 |
Endpoint of concern | Irritant - eye, skin, and respiratory system |
Equation | A |
LOAEL[ADJ] (mg/m3) | 5E-1 |
Uncertainty factor | 60 |
Styrene (100-42-5)
Acute HRV (µg/m3) | 21,000 |
Endpoint of concern | Irritant - eye and respiratory system |
Equation | A |
NOAEL[ADJ] (mg/m3) | 2.1E2 |
Uncertainty factor | 10 |
Tetrachloroethylene or perchlorethylene (127-18-4)
Acute HRV (µg/m3) | 20,000 |
Endpoint of concern | Irritant - eye and respiratory and nervous systems |
Equation | B |
LOAEL[ADJ] (mg/m3) | 1.2E3 |
Uncertainty factor | 60 |
Toluene (108-88-3)
Acute HRV (µg/m3) | 37,000 |
Endpoint of concern | Irritant - eye and respiratory and nervous systems |
Equation | B |
NOAEL[ADJ] (mg/m3) | 3.7E2 |
Uncertainty factor | 10 |
1,1,1-Trichloroethane or methyl chloroform (71-55-6)
Acute HRV (µg/m3) | 140,000 |
Endpoint of concern | Nervous system |
Equation | A |
NOAEL (mg/m3) | 1.37E3 |
Uncertainty factor | 10 |
Trichloroethylene (79-01-6)
Acute HRV (µg/m3) | 2,000 |
Endpoint of concern | Reproductive/developmental |
Equation | D |
LOAEL (mg/m3) | 5.4E2 |
Uncertainty factor | 300 |
Triethylamine (121-44-8)
Acute HRV (µg/m3) | 2,800 |
Endpoint of concern | Irritant - eye; transient corneal edema |
Equation | B |
NOAEL[ADJ] (mg/m3) | 2.8E1 |
Uncertainty factor | 10 |
Vanadium pentoxide (1314-62-1)
Acute HRV (µg/m3) | 30 |
Endpoint of concern | Irritant - respiratory system |
Equation | B |
LOAEL[ADJ] (mg/m3) | 3E-1 |
Uncertainty factor | 10 |
Xylenes (1330-20-7)
Acute HRV (µg/m3) | 43,000 |
Endpoint of concern | Irritant - eye and respiratory and nervous systems |
Equation | A |
NOAEL (mg/m3) | 4.3E2 |
Uncertainty factor | 10 |
* This HRV is for a chemical where there is little magnitude difference between the level where mild irritancy occurs and levels where more severe adverse health effects occur.
** This HRV is for a chemical mixture which, therefore, does not have a chemical-specific number assigned by the Chemical Abstracts Service.
MS s 144.12
26 SR 1229; 26 SR 1395
January 4, 2016
The heading for each item contains the chemical name and, in parenthesis, the CAS RN. Each item lists the MHRV and the variables necessary for the equation. The equations used to develop the MHRV are designated as follows: "A" means applying the equation under part 4717.8350 for noncarcinogenic effects of toxicants and "B" means applying the equation under part 4717.8450 for carcinogens. The endpoint of concern is listed for use in determining a cancer index under part 4717.8550 or a hazard index under part 4717.8600.
TABLE OF MHRVs
Antimony (7440-36-0)
MHRV (µg/kg-day) | 0.4 |
Endpoint of concern | Hematologic system |
Equation | A |
LOAEL (mg/kg-day) | 3.5E-1 |
Uncertainty factor | 1,000 |
Arsenic (7440-38-2)
MHRV (µg/kg-day) | 0.007 |
Endpoint of concern | Cancer |
Equation | B |
Potency slope [mg/kg-day]-1 | 1.5 |
Benzo[a]pyrene (50-32-8)
MHRV (µg/kg-day) | 0.001 |
Endpoint of concern | Cancer |
Equation | B |
Potency slope [mg/kg-day]-1 | 7.3 |
Cadmium (7440-43-9)
MHRV (µg/kg-day) | 0.5 |
Endpoint of concern | Renal system |
Equation | A |
NOAEL (mg/kg-day) | 5E-3 |
Uncertainty factor | 10 |
Manganese (7439-96-5)
MHRV (µg/kg-day) | 140 |
Endpoint of concern | Nervous system |
Equation | A |
NOAEL (mg/kg-day) | 1.4E-1 |
Uncertainty factor | 1 |
Methylmercury (22967-92-6)
MHRV (µg/kg-day) | 0.1 |
Endpoint of concern | Nervous system and developmental |
Equation | A |
BMD (mg/kg-day) | 1E-3 |
Uncertainty factor | 10 |
Nickel (7440-02-0)
MHRV (µg/kg-day) | 20 |
Endpoint of concern | Decreased body and organ weights |
Equation | A |
NOAEL (mg/kg-day) | 5 |
Uncertainty factor | 300 |
Polychlorinated biphenyls (PCB) (1336-36-3)
MHRV (µg/kg-day) | 0.05 |
Endpoint of return | Developmental |
Equation | A |
LOAEL (mg/kg-day) | 5E-4 |
Uncertainty factor | 10 |
MS s 144.12
26 SR 1229
May 11, 2009
This part establishes the method for determining the health risk values (HRVs) for noncarcinogenic effects of toxicants.
The equation for calculating an HRV for a noncarcinogenic effect of a toxicant is:
HRV = |
NOAEL[ADJ] or LOAEL[ADJ] or BMC[ADJ] ----------------------------------------------------- (Uncertainty factor)(Modifying factor) |
× 1,000 |
or
HRV = |
NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] ----------------------------------------------------- (Uncertainty factor)(Modifying factor) |
× 1,000 |
Where:
NOAEL[ADJ] or [HEC], LOAEL[ADJ] or [HEC], or BMC[ADJ] or [HEC] is expressed in units of milligrams per cubic meter (mg/m3) of air;
The equation for calculating a NOAEL[HEC], LOAEL[HEC], or BMC[HEC] for a particle having a respiratory effect is:
NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] = |
NOAEL[ADJ] or LOAEL[ADJ] or BMC[ADJ] × RDDR |
Where:
NOAEL[HEC], LOAEL[HEC], or BMC[HEC] is expressed in units of milligrams per cubic meter (mg/m3) of air;
NOAEL[ADJ], LOAEL[ADJ], or BMC[ADJ] is expressed in units of milligrams per cubic meter (mg/m3) of air; and
The equation for calculating a NOAEL[HEC], LOAEL[HEC], or BMC[HEC] for particles with an extrarespiratory effect is:
NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] = |
NOAEL[ADJ] or LOAEL[ADJ] or BMC[ADJ] × RDDRER |
Where:
NOAEL[HEC], LOAEL[HEC], or BMC[HEC] is expressed in units of milligrams per cubic meter (mg/m3) of air;
NOAEL[ADJ], LOAEL[ADJ], or BMC[ADJ] is expressed in units of milligrams per cubic meter (mg/m3) of air; and
The equation for calculating the NOAEL[HEC], LOAEL[HEC], or BMC[HEC] for a gas having a respiratory effect is:
NOAEL[HEC] or LOAEL[HEC] or BMC[HEC] = |
NOAEL[ADJ] or LOAEL[ADJ] or BMC[ADJ] × RGDR |
Where:
NOAEL[HEC], LOAEL[HEC], or BMC[HEC] is expressed in units of milligrams per cubic meter (mg/m3) of air;
NOAEL[ADJ], LOAEL[ADJ], or BMC[ADJ] is expressed in units of milligrams per cubic meter (mg/m3) of air; and
RGDR is the regional gas dose ratio in the specific region of the respiratory tract and is unitless.
The equation for calculating the NOAEL[HEC], LOAEL[HEC], or BMC[HEC] for a gas having an extrarespiratory effect is:
(Hb/g)A | |
NOAEL[HEC] = NOAEL[ADJ] × | ----------- |
(Hb/g)H |
or
(Hb/g)A | |
LOAEL[HEC] = LOAEL[ADJ] × | ----------- |
(Hb/g)H |
or
(Hb/g)A | |
BMC[HEC] = BMC[ADJ] × | ----------- |
(Hb/g)H |
Where:
NOAEL[HEC], LOAEL[HEC], or BMC[HEC] is expressed in units of milligrams per cubic meter (mg/m3) of air;
NOAEL[ADJ], LOAEL[ADJ], or BMC[ADJ] is expressed in units of milligrams per cubic meter (mg/m3) of air; and
(Hb/g)A/(Hb/g)H is the ratio of the blood:gas (air) partition coefficient of the chemical in the experimental animal to the blood:gas (air) partition coefficient of the chemical in a human; the ratio is unitless. If (Hb/g)A > (Hb/g)H or if the partition coefficient values are unknown, (Hb/g)A/(Hb/g)H = 1.0.
MS s 144.12
26 SR 1229; 26 SR 1395
May 11, 2009
This part establishes the method for determining the multimedia health risk value (MHRV) for a noncarcinogenic effect of a toxicant emitted to the air.
The equation for calculating a MHRV for a noncarcinogenic effect of a toxicant is:
NOAEL or LOAEL or BMD | ||
MHRV = | -------------------------------------------------- | × 1,000 |
(Uncertainty factor) (Modifying factor) |
Where:
MHRV is expressed in units of micrograms of chemical or defined mixture of chemicals per kilogram of body weight per day (µg/kg-day);
NOAEL, LOAEL, or BMD is expressed in units of milligrams of chemical or defined mixture of chemicals per kilogram body weight per day (mg/kg-day);
MS s 144.12
26 SR 1229; 26 SR 1395
May 11, 2009
This part establishes the method for determining the health risk values (HRVs) for a carcinogen.
MS s 144.12
26 SR 1229
May 11, 2009
This part establishes the methods for determining the multimedia health risk values (MHRVs) for carcinogens emitted to the air.
The general equation for calculating MHRVs for carcinogens is:
Additional lifetime risk | ||
MHRV = | -------------------------------- | × 1,000 |
Potency slope |
Where:
potency slope is expressed in units of the inverse of milligrams per kilogram of body weight per day (mg/kg-day)-1;
MS s 144.12
26 SR 1229
May 11, 2009
This part establishes the method for determining the health risk value (HRV) for toxicants having acute toxicity effects.
The equation for calculating an HRV for an acute irritant is:
NOAEL or NOAEL[ADJ] | ||
HRV = | -------------------------------------------------- | × 1,000 |
(Uncertainty factor)(Modifying factor) |
or
LOAEL or LOAEL[ADJ] | ||
HRV = | -------------------------------------------------- | × 1,000 |
(Uncertainty factor)(Modifying factor) |
or
BMC or BMC[ADJ] | ||
HRV = | -------------------------------------------------- | × 1,000 |
(Uncertainty factor)(Modifying factor) |
Where:
NOAEL, NOAEL[ADJ], LOAEL, LOAEL[ADJ], BMC, or BMC[ADJ] is expressed in units of milligrams per cubic meter (mg/m3) of air;
For acute irritants where the study time is 30 minutes to two hours, the study NOAEL or LOAEL will be used without adjustment. For studies where the exposure time is 30 minutes to two hours and a BMC approach is used, a time adjustment may be necessary. When a BMC approach is used, the equation for calculating a BMC[ADJ] is:
BMC[ADJ] x 60 minutes = BMC(study) x exposure duration |
Where:
BMC(study) is expressed in units of milligrams of a chemical or defined mixture of chemicals per cubic meter (mg/m3) of air used in the study as the exposure concentration; and
The equation for calculating a NOAEL[ADJ], LOAEL[ADJ], or BMC[ADJ] for an acute irritant based on data from a study where the exposure time or adverse health effect onset time is greater than two hours but less than or equal to eight hours is:
(NOAEL(study)n or LOAEL(study)n or BMC(study)n) (exposure duration or onset of critical effect) = NOAEL[ADJ] or LOAEL[ADJ] or BMC [ADJ]
Where:
NOAEL(study), LOAEL(study), or BMC(study) is expressed in units of milligrams of a chemical or defined mixture of chemicals per cubic meter (mg/m3) of air used in the study as the exposure concentration;
the exposure duration represents the time at which the critical effect occurred. This most often is the exposure duration, but in some instances the critical effect may differ from the exposure duration, depending on the critical endpoint being observed; and
NOAEL[ADJ], LOAEL[ADJ], or BMC[ADJ] is expressed in units of milligrams per cubic meter (mg/m3) of air.
The equation for calculating an HRV for a chemical or defined mixture of chemicals causing reproductive/developmental toxicity is:
NOAEL or LOAEL or BMC | ||
HRV = | -------------------------------------------------- | × 1,000 |
(Uncertainty factor)(Modifying factor) |
Where:
MS s 144.12
26 SR 1229; 26 SR 1395
May 11, 2009
To evaluate simultaneous exposure for multiple carcinogens, a cancer index must be calculated using the procedure in this part.
For health risk values (HRVs) that have cancer endpoints, items A to C apply.
A cancer index is determined for chemicals or defined mixtures of chemicals with an inhalation endpoint of cancer using the following equation:
Cancer index = |
E
C1
_ HRV C1 |
+ |
E
C2
_ HRV C2 |
+ . + |
E
Cn
_ HRV Cn |
Where:
ECn represents the measured or modeled ambient air concentration as expressed in units of micrograms per cubic meter (µg/m3) of the first, second, through the nth carcinogen; and
HRVCn represents the chronic HRV of the first, second, through nth carcinogen as expressed in units of micrograms per cubic meter (µg/m3).
A cancer index of one is equivalent to a cumulative HRV. A cancer index greater than one exceeds the cumulative HRV.
For mixtures of multimedia health risk values (MHRVs) that have cancer endpoints, items A to C apply.
A cancer index is determined for chemicals or defined mixtures of chemicals with an endpoint of cancer using the following equation:
Cancer index = |
D
C1
_ MHRV C1 |
+ |
D
C2
_ MHRV C2 |
+ . + |
D
Cn
_ MHRV Cn |
Where:
DCn represents the calculated lifetime averaged daily dose of the first, second, through the nth carcinogen as expressed in units of micrograms per kilogram of body weight per day (µg/kg-d); and
MHRVCn represents the MHRV of the first, second, through the nth carcinogen as expressed in units of micrograms per kilogram of body weight per day (µg/kg-d).
A cancer index of one is equivalent to a cumulative MHRV. A cancer index greater than one exceeds the cumulative MHRV.
MS s 144.12
26 SR 1229
May 11, 2009
When simultaneous exposure is evaluated for multiple toxicants with noncarcinogenic effects, a hazard index must be calculated using the procedure in this part.
For health risk values (HRVs) that have endpoints other than cancer, items A to D apply.
The chemicals or defined mixtures of chemicals detected in the air must be first grouped by endpoint of concern and by HRV type (acute, subchronic, chronic).
A separate hazard index is then calculated for each same endpoint of concern group within the chronic, subchronic, and acute categories.
When two or more chemicals or defined mixtures of chemicals have the same endpoint, a hazard index must be determined using the following equation:
Hazard index = |
E
ST1
_ HRV ST1 |
+ |
E
ST2
_ HRV ST2 |
+ . + |
E
STn
_ HRV STn |
Where:
ESTn represents the measured or modeled ambient air concentration of the first, second, through the nth toxicant with noncarcinogenic effects in air as expressed in units of micrograms per cubic meter (µg/m3); and
HRVSTn represents the HRV of the first, second, through the nth toxicant with noncarcinogenic effects as expressed in units of micrograms per cubic meter
(µg/m3).
A hazard index of one or less indicates a combined concentration of chemicals unlikely to cause an adverse health effect to the general public.
For multimedia health risk values (MHRVs) that have endpoints other than cancer, items A to C apply.
The chemicals or defined mixtures of chemicals measured or modeled in ambient air must first be grouped by endpoint of concern.
When two or more chemicals or defined mixtures of chemicals have the same endpoint, a hazard index must be determined using the following equation:
Hazard index = |
D
ST1
_ MHRV ST1 |
+ |
D
ST2
_ MHRV ST2 |
+ . + |
D
STn
_ MHRV STn |
Where:
DSTn represents the calculated dose of the first, second, through the nth toxicant with noncarcinogenic effects as expressed in micrograms per kilogram of body weight per day (µg/kg-d); and
MHRVSTn represents the MHRV of the first, second, through the nth toxicant with noncarcinogenic effects as expressed in micrograms per kilogram of body weight per day (µg/kg-d).
A hazard index of one or less indicates a combined concentration of chemicals unlikely to cause an adverse health effect to the general public.
MS s 144.12
26 SR 1229; 26 SR 1395
May 11, 2009
Official Publication of the State of Minnesota
Revisor of Statutes